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Cardiovascular disease is the leading cause of death worldwide. When a myocardial 
infarction occurs, scar tissue compensates the damaged myocardial tissue. This scar 
tissue increases the stiffness of the heart tissue, reduces the heart’s function, and finally 
leads to the heart failure (HF) disease.  To have the tissue engraftment, in-vitro cardiac 
tissue should have the same properties as the native mature cardiac tissue.  However, 
current in-vitro cell culture technologies fail to accurately recreate the in-vivo like 
mechanically physiological environment for in-vitro cardiac tissue culture, and therefore, 
fail to regenerate the in-vivo like mature cardiac tissue.  Hence, a microfluidic cardiac cell 
culture model (CCCM) system was developed to better recreate the cellular environment 
and advance cardiac regeneration. CCCM system replicates the hemodynamic loading 
and unloading conditions occurring inside the left ventricle of a heart.  With this system, 
different pressures of human heart conditions may be replicated for a variety of clinical 
and physiologic conditions.   For proof-of-concept, embryonic chick cardiac cells with 
normal heart condition were applied.  Compared to the tissue cultured in a static 
condition, tissues stimulated in the CCCM system achieved an in-vivo like cardiac 
vii 
 
matured phenotype, had higher proliferating rate, showed more maturity, and expressed 
more contractile proteins.  These results demonstrated that the CCCM system can be used 
to study the behavior of cardiomyocytes in different mechanical heart conditions and to 
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   CHAPTER 1 
INTRODUCTION 
 
1.1.  CARDIOVASCULAR DISEASE (CVD) 
 
The basic components of the cardiovascular system are the heart, blood vessels (arteries, 
capillaries, and veins), autonomic innervation of the heart and vasculature, and the 
circulating blood. The heart acts as a pump to circulate blood through the lungs to 
oxygenate, and through the arteries to deliver oxygen and nutrients to the entire body.  
When blood is delivered to tissues, the oxygen and carbon dioxide are exchanged. The 
deoxygenated blood is then returned to the heart via veins, and finally to the lungs, 
helping dispose of carbon dioxide and other waste products.  
 
Cardiovascular Disease (CVD) collectively refers to abnormalities associated with 
various components of the cardiovascular system and covers over 60 disorders relating to 
the heart and vascular system.  CVD is the leading cause of death in the United States, 
which is higher than the next four leading causes of death combined.1  Statistics from the 
American Heart Associate (AHA) indicate that about 81 million people or 1/4th of the 
population suffer from some form of CVD in the United States.  This includes high blood 
pressure ~ 74.5 million; coronary heart disease ~ 17.6 million; stroke ~ 6.4 million; 
congenital cardiovascular defects ~ 650,000 to 1.3 million; and heart failure ~ 5.8 
million.2   Based on the article: “Heart Disease and Stroke 2010 Update” from AHA, it 
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was estimated that the total indirect and direct cost due to CVD and stroke in 2010 would 
be ~ 503.2 billion dollars, placing a severe burden on the economy and diminishing the 
quality of life for several thousands of people.2-4  
 
CVD can be classified into two major categories based on disorders of the heart or the 
vascular system.  Disorders of the heart include conditions such as angina pectoris, 
arrhythmias, cardiomyopathy, congestive heart failure, and congenital heart disease.  
Disorders of the vascular system, on the other hand, include conditions such as aortic 
aneurysms, arteriosclerosis, high blood pressure, stroke, and transient ischemia.1, 5 
Coronary heart disease is the most common type of CVD.   It is a condition which fatty 
deposits build up inside the inner walls of coronary arteries, creating blockages of the 
arteries.  These blockages reduce the blood flow, causing a pain or discomfort in the 
chest, heart failure (HF) and heart attacks.  In atherosclerosis,, the arteries become thicker 
or harden; and the inner wall of the arteries becomes narrower due to the deposits of fat, 
cholesterol or other substances.  This narrowed passage can block the blood flow and 
lead to heart attacks and strokes.  Strokes occur when the blood vessels to the brain are 
occluded or broken.  As a result, brain cells begin to die due to lack of oxygen and 
nutrition.2-4  Stroke usually relates closely to high blood pressure, which happens when 
the pressure inside the vessels is higher than the normal range, which is about 120/80 
mmHg.   High blood pressure can cause HF, stroke, kidney failure, or other health 
problems.  The end stage for different CVDs is HF (Fig.1.1) which occurs when the heart 
fails to pump sufficient blood through the body.  The body, therefore, does not get 
enough oxygen and nutrients. HF may develop slowly over time, and if not treated, can 
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cause life-threatening conditions, including pulmonary edema, failure of brain, kidney 
and other major organs, and myocardial infarction.6-9 
                                    
Figure 1.1: Heart Failure is the end-stage of dysfunctional cardiovascular system existing 
for a long term.  
 
1.2.  TREATMENT OF HEART FAILURE 
Heart Failure (HF) is a chronic disease, therefore, the treatment for HF needs lifelong 
management, which includes changes in living habits, medication, and assist devices to 
augment heart function. 7, 10, 11  The only cure for end- stage heart failure is total heart 
transplantation. 
 
Drug therapy is usually used for the initial stage of the HF.  Depending on the stage and 
symptoms of HF, a single or combination of different medications are applied.  The most  
common drugs used for treatment of HF include Angiotensin-converting enzyme 
inhibitors, or Angiotensin II receptor blockers, Digoxin (Lanoxin), Beta blockers, 
Diuretics, and Aldosterone antagonists.12  Angiotensin-converting enzyme inhibitors or 
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Angiotensin II receptor blockers dilate the arteries and improve blood flow, therefore, 
decrease the workload on the heart.  Digoxin helps to strengthen the contraction of heart 
muscle and slow the heartbeat.  Beta blockers reduce the heart rate and pressure.  
Diuretics enhance urination frequency to keep from the fluid building up in the body, 
especially in the lungs.   Aldosterone antagonists help the heart work better.  
 
When the HF advances to a more serious stage, devices that optimize myocardial 
function may be used for the treatment.  For example, implantable cardioverter-
defibrillators are used for monitoring the heart rhythm.  Cardiac resynchronization 
therapy, or biventricular pacing, are used to help the heart pump efficiently by sending 
timed electrical impulses to the heart's ventricles for contraction.  Mechanical circulatory 
support devices (left ventricular assist devices (LVAD) ) that unload the native ventricle 
are used as a bridge to transplantation or as destination therapy in patients with severe HF 
that are refractory to medical therapy.13  LVADs are mechanical pumps designed to 
transport blood from the left ventricle through the body.   
 
Heart transplant is a palliative therapy used for a subset of pediatric and adult patients 
with progressive and irreversible HF.   A healthier heart from a donor is replaced for the 
failing diseased heart.14   However, people undergoing heart transplant face high risks of 
the rejection of the donor heart, infection, artery problems, medication side effects and 
the potential high risk of cancer due to the immune-suppressant medications.14  In 
addition, due to the shortage of donors, people who need heart transplants experience a 
long waiting times.   Heart transplant or LVAD are currently the only options for the end-
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stage HF.  However, due to the lack of donors and the complications associated with 
immunosuppressive treatments as well as many high risks occurred during surgery, 
scientists and surgeons continue to search for new strategies to treat the HF.  
 
1.3.  THE HEART 
1.3.1. Overview of the formation of the heart in the embryo 
The heart is one of the first functioning organs formed during the embryonic period, both 
in bird and mammalian embryos.15, 16  The heart derives from the anterior mesoderm, the 
middle embryonic layer.  First, one group of the mesodermal cells differentiate into 
precardiac cells, which later transform into myocardial, endothelial and smooth muscle 
cells.  These mesodermal precardiac cells migrate and form the primitive linear heart 
tube, which includes the inner endothelial, cardiac jelly, and external myocardial layers.   
Another population of cardiac cells differentiates into cardiac myocytes, smooth muscle 
cells, and endothelial cells.17, 18 Then, the primitive straight heart tube loops and folds 
into an S-shape, followed by the convergence process.  During this convergence phase, 
the formation of trabeculae begins; and hemodynamic stimulation plays an important role 
in modulating the  trabecular patterning and development.19 The heart surface area, 
myocardial mass and wall stiffness increase as a result of this trabecular formation.  At 
the end of this formation, the trabecular compaction begins, which contributes to the 
formation of ventricular septum and the thickness of the ventricular compact layer.  At 
this time, the separation between the atria and ventricles, via the inlet segment, occurs 
and the formation of atria and ventricle develops.17, 20  Following the convergence is the 
wedging process.  The modification of valves, such as the aortic valve or atria-ventricular 
valves, occurs; and the separation of left and right atria and ventricles is completed to 
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form a regular 4-chamber heart. 15, 19, 20, 19 Any abnormality during these processes can 
lead to heart congenital heart defects.  
 
A complete 4-chamber heart, through one organ, functions as two pumps coupled to one 
another in a series.  The right pump receives deoxygenated blood from the entire body 
and pumps it to the lungs for oxygen-carbon dioxide exchange, while the left pump 
receives the oxygenated blood from the lung and then delivers this oxygenated blood to 
the entire body.  As a result, the pressure in the right pump is lower than in the left pump.  
However, to perform pumping function, both the left and right pumps need to match their 
output volume.  
 
1.3.2. Gross anatomy of the heart 
Each side of a heart has a main pumping chamber (the ventricle), a holding chamber (the 
atria), and two valves to prevent back flow (Fig. 1.2.).  The valve between the right atria 
and right ventricle is the tricuspid valve and between the left atria and left ventricle is the 
mitral valve.21, 22  These valves prevent the retrograde flow of blood back into the atrium 
when the ventricles contract.  The pulmonic valve and aortic valve in the right and left 
ventricle respectively prevent the blood in the pulmonary artery and aorta from flowing 
back to the right and left ventricle when these ventricles relax.  The two ventricles share a 
common wall (septum) and electrical system to stimulate and control the timing of native 
ventricular contraction.   
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Figure 1.2:  Schematic image of the heart gross anatomy.  
      (http://healthinformation.4arabs.com/heart/2.html) 
 
Deoxygenated blood from the vena cava system flows to the heart and is held in the right 
atria.  When the tricuspid valve opens, the blood flows into the right ventricle in order to 
be pumped to the lung where the exchange of carbonate-oxygen in the blood occurs.  
Through the pulmonary artery, the oxygenated blood is then brought to the left atria and 
finally is pumped into the left ventricle when the mitral valve opens.  The contraction of 
the left ventricle pumps the blood into the aorta from where blood is delivered throughout 
the body.  Due to the vascular resistances and pressures being higher in the systemic 
circulation than the pulmonary circulation, the left ventricle generates more force to 
pump.  Therefore, the muscle wall of the left ventricle is thicker than the right ventricle.  
Atria act as a booster pump and hence the walls of the atria are also much thinner than the 
ventricles.21, 22  




1.3.3. Working of the heart 
The heart, consists of two atria and two ventricles, is the organ responsible for pumping 
blood throughout the body. The electrical signals generated in the sino atrial node travel 
through a signal transduction pathway to stimulate the heart tissue.   In response to this, 
the upper then lower chambers of the heart contract sequentially, first both atria, then the 
ventricles.  The working principle of the right heart side is similar to the left heart. 
 
A pumping cycle of the heart can also be divided into two main periods: the diastolic and 
systolic periods. The diastolic period starts when the aortic valve closes and the muscles 
begin to relax.  The diastolic period ends when the mitral valve closes after filling the 
blood from the atrium to the ventricle. The systolic period then starts when the mitral 
valve closes and the muscle begins to contract.  This period ends when the aortic valve 
closes after the blood in the ventricle is ejected to the aorta.21-23 
 
The relationship between pressure and volume, especially for the left ventricle (LV) 
chamber, can be divided into four phases: the ventricular filling or diastole, isovolumic 
contraction, ejection, and isovolumic relaxation (Fig.1.3.).21-24  During the ventricular 
filling phase, the relaxation of the heart muscles reaches the maximum level.  Therefore, 
when the blood from the atria continues to fill in the ventricle, the pressure of the 
ventricle goes up gradually and the blood volume is increased significantly, which is 
represented by phase ‘a’ on the pressure-volume loop.  When the ventricle pressure 
reaches a certain level, the muscles contract.24  The pressure inside the ventricle at this 
point is higher than the atria.  As a result, the mitral valve closes, but this pressure is not 
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sufficient to open the aortic valve.  Because all valves are closed, the pressure is 
increased dramatically while the volume remains the same.  This phase is called the 
isovolumic contraction phase (phase b).  At this point, the ventricle begins to contract 
until the pressure inside the ventricle chamber exceeds the aortic pressure; then the aortic 
valve opens.  The blood inside the left ventricle is then ejected to the aorta, causing a 
decrease in volume (phase c).  However, since the ventricle is still contracting, the 
pressure inside the ventricle keeps increasing until it reaches its peak, then, decreases 
when the ventricle begins to relax.  The ventricular pressure begins to drop until the 
pressure in the aorta finally becomes larger than in the ventricle, causing the closure of 
the aorta valve.  The relaxation of the ventricle plus the closure of valves greatly reduces 
the pressure inside the ventricle while the volume remains unchanged with no blood 
going in or out of the ventricle.  This phase (phase d) generates a vertical line (isovolumic 
relaxation phase) on the diagram B (Fig.1.3.).  When the pressure inside the LV is lower 
than the left atria pressure, the mitral valve opens and the LV is again filled with blood. 
The next cardiac cycle begins.21-24  
 
During normal adult conditions, the human heart rate is about 70 ± 10 beats per minute 
(bpm). The stroke volume is about 60 ± 10 mL/beat and the left ventricular systolic peak 
pressure approximates of 120 ± 10 mmHg.  The left ventricular end diastolic pressure 
ranges from 5-12 mmHg. 25, 26.  Stroke volume is the volume of blood ejected for each 






Figure 1.3:  Relationship between pressure and volume during the pump cycle of the 
heart. (A) Cardiac cycle diagram and (B) Pressure-Volume Loop.  (a) Diastolic filling 
phase, (b) Isovolumic phase, (c) ejecting phase, and (d) Isovolumic relaxation phase. 
 
1.4.   HEART AT CELLULAR LEVEL 
1.4.1. Cellular organization of cardiac tissue 
Unlike other tissue, in the early development, embryonic cardiac tissue has a high ability 
for both differentiation and proliferation.27-29   This high proliferation and differentiation 
makes the vertebrate heart quickly transformed from a single two-layer straight tube into 
a four-chamber heart.30  Cardiac morphogenesis occurs during the embryonic period, 
between weeks 4 to 8 in human pregnancy, or between days 2-10 in  the chick embryo.16  
DNA synthesis reaches the high rate during this cardiac morphogenesis; and the cardiac 
conduction system as well as coronary vascular system develops in late morphogenesis.16, 
31 However, when entering the neonatal period, cardiomyoctes reduce their proliferating  
rate to focus more on producing contractile proteins; hence, becoming functional 
cardiacmoyctes.32  Therefore, cardiomyocyte differentiation occurs to adapt the 
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subsequent of hemodynamic pressure/volume loading and unloading, resulting in an 
increase in size or causing cell hypertrophy.  During this hypertrophic process, the 
amount of protein contents (especially contractile proteins) per individual cell increases 
with a little change in cell number.33, 34 After birth, cardiomyocytes lose their ability to 
proliferate. 
 
The embryonic cardium is composed of three different major cell layers: an inner single 
cell endocardial layer, a loose connective tissue layer and the layer of cardiomyocyte 
muscle cells (or myocardium layer).14, 21, 22, 35  During the morphogenesis,  via 
proliferation and differentiation of cardiomyocytes, these three layers are quickly 
transformed into a 3D trabecular myocardium. (Fig. 1.4.A) This trabecular and compact 
myocardium continues to increase in mass and number in order to form a solid mature 
myocardium to sustain the transmural pressure due to the hemodynamic loading and 
unloading applied on the inner side of the cardiac muscle wall.16  Hence, the developing 
of this solid mature myocardium promotes the myocardium function.36, 37  To perform 
this function, under the effect of mechanical load, mature cardiomyocyte and myofibril 
arrange in parallel. 35 
 
Cardiomyocytes are the cells that make up the heart muscle and have the ability to 
contract spontaneously.  To perform their function in synchrony, cardiomyocytes need to 
align and establish end to end cell-cell contacts. (Fig.1.4B and C).   Smooth muscle cells 
form a contiguous layer over the cardiomyocytes, and finally a layer of endothelial cells 
line the myocardium providing shear protection. Besides these major cell types, cardiac 
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tissues are also composed of cardiac fibroblasts.  Cardiac fibroblasts relate to heart 
remodeling, therefore, play a critical role in heart hypertrophy and heart failure.38 
                                                                  
                                          
                                                                 
Figure 1.4:  Cardiac tissue. [A] Schematic layers of the heart walls; [B] Histological 
image of ventricular wall; [C] Arrangement of cardiomyocytes in the cardiac muscle.  
([A] 
39









Hemodynamic stimulation is one of the major exogenous factors regulating cardiac 
morphogenesis. To adapt mechanical loading and unloading, the myocardium increases 
the cell size with protein contents, especially the contractile regulating proteins.16, 40  
Myofibril is the contractile structure of cardiac muscle.  Myofibrils are composed of 
sarcomeres or the contractile unit. 41, 42  At the beginning, when the cardiac muscle cells 
differentiate, all the sarcomeric proteins randomly diffuse in the cytoplasm.  By the time 
of linear-heart-tube formation, due to mechanical stimulations, myocytes begin to beat or 
contract, causing myofibrils to rapidly arrange into a highly organized network in order to 
synchronize the contractions throughout.  A sarcomere unit is composed of 3 major 
components: thin filament, thick filament, and Z band. (Fig. 1.5) Thick filaments arrange 
in parallel to the thin filaments.  Myosin heavy chain proteins are on the thick filament 
and bind to F-actin of the thin filament during the contraction. Thin filament is composed 
of F-actin, troponins, and tropomyosin.  During the contraction, thick and thin filament 
slide along each other.  Titin filament connects the thick filaments to the Z band and acts 
as an elastic spring during the myocyte contraction.  The Z band connects the sarcomere 
units in series.42-44  The contraction is controlled by the interaction between the myosin 
heavy chain on the thick filament and the binding site of the F-actin molecules, which is 
the major component of the thin filament.  This binding activity depends on the 
sensitivities of Ca2+ to the tropomyosin-troponin complex.45 Alpha-actinin, a component 
of Z band, serve as the anchor for F-actin to Z band, as well as the connection to neighbor 
sarcomere.46  The mechanism of the contraction will be discussed in the section 1.4.2.   
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Figure 1.5: Simplified schematic model of mature myofibril. [A] Myofibril; [B] 
Ultrastructure of a relaxing sarcomere; [C] Ultrastructure of a contracting sarcomere. 
The magnitude and duration of stretch and contraction in a cardiac tissue depends on the 






refers to the condition when the filling of the blood inside the ventricle causes the stretch 
of the ventricular wall during the diastolic phase.  Afterload refers to the aortic resistance 
that the system needs to overcome in order to pump blood out of the ventricle via opening 
of the aortic valve.22  This directly affects the contractile force that needs to be generated 
by cardiomyocytes. Overcoming the aortic pressure opens the aortic valve for ejecting the 
blood into the aorta.   
 
Preload pressure increases slowly when blood filling to the chamber during diastole 
increases, which creates greater systolic pressure for the subsequent contractions due to 
the preload sensitivity of the native ventricle.  This systolic pressure continues to increase 
until its maximum systolic pressure is reached at the optimal preload.  At a constant 
preload, higher systolic pressure can be obtained through ventricular contraction by 
raising the afterload condition such as increasing the aortic pressure.22  However, if the 
afterload pressure or the resistance keeps increasing, the ventricle cannot create enough 
force to open the aortic valve to push the blood out of the heart.  At this point, the systolic 
phase is totally isovolumic.  Preload and afterload pressures, as a result, depend on the 
vascular system and the behavior of the heart including peripheral resistance, the 
frequency of the heart’s contraction, and change of the stroke volume.22 
 
 
1.4.2. Cellular response to mechanical signals 
 
When a mechanical stimulus is applied to the extracellular matrix (ECM), the cells detect 
this mechanical stimulus via mechanoreceptors. These mechanoreceptors are located in 
the plasma membrane connecting the extracellular and intracellular regions of the cells, 
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traducing the mechanical signals from the outside to the inside of the cell.23, 47    Once the 
signal is transmitted inside of the cell, the signal triggers biochemical changes via 
signaling transduction pathway, enhances the formation of sarcomere, and alters structure 
of the cytoskeleton directly.23, 47  
 
Troponin complex includes troponin C (TnC), troponin I (TnI), and troponin T (TnT). 
TnC is Ca2+ sensitive and has a site for Ca2+ binding; TnI is the contractile inhibitor; and 
TnT is the protein binding to tropomyosin.  This troponin complex is strongly associated 
with the tropomyosin, which regulate the binding of MHC to the thin filament for 
sarcomeric contraction. 48-50  Binding Ca2+ to TnC switches the conformation of TnC 
from a close position to the open one, allowing the interaction of TnC with TnI to 
happen. Without this interaction, TnI binds to F-actin at the binding site of MHC; thus, it 
prevents the bonding between MHC with F-actin.  Binding of TnC-TnI releases the 
binding of TnI-actin and enhances the binding of TnI-TnT, which reveals the binding 
sites of MHC for MHC attachment.   Once MHC attaches to the F-actin, with the ATP 
hydrolysis occurring during the association of Ca2+ with TnC; contraction takes place. 41, 
50, 51 The relaxation of the sarcomere unit occurs during the dissociation of Ca2+-TnC. 
Ca2+ is then transferred back to SR via the SERCA2a pump.  In summary, calcium ion 
will bind to the troponin C, help to deactivate troponin I (inhibitor) and change the 
formation of TnT in order to reveal the MHC binding site on the thin filament. Once the 
binding site is opened, myosin heavy chain from the thick filament binds to F-actin.  This 
binding pulls the thin filament of a sarcomere closer to the center, causing the 
contraction.  Titin is a protein connecting the thick filament to the Z band at this point 
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serves as an elastic spring, keeping the thick filament at the center during this contraction.  
Alpha actinin, a protein located on the Z bands, helps to connect the thin filament with 
the sarcomere, as well as to the thin filament of the neighbor sarcomere.  Alpha actinin 
thus contributes to form and maintain the lattice networks among the sarcomere during 
the relaxing as well as the contracting phases.  
 
Catecholamine affects mechanical performance of the heart tissues through the activation 
of β-adrenergic receptors (AR) and cardiovascular function can be positively and 
negatively controlled primarily via adrenergic signaling.52-54  Under normal physiological 
conditions, catecholamine induces positive inotropic and lusitropic responses in the heart 
tissue through β1-AR-activated pathway.  Once the stimulation of β1-ARs binding with 
its agonist (ex. isoproterenol) happened, this binding complex activates the formation of 
cyclic AMP (cAMP).  cAMP accumulation rapidly increases which indirectly promotes 
the phosphorylation of PLB, and enhances the cardiac contractility. 47   Even though the 
density of β-ARs in utero diminishes during development,55 there are shifts in the 
adrenergic receptor subtypes with increasing dominance by subtype β1-ARs as 
cardiomyocytes become more mature under normal physiological condition.53, 56 This 
dominant β1-ARs, therefore, induces positive inotrope and lusitrope via heart rate and 
contractility.  Under the abnormal physiological condition of the heart, or failing heart, 
β1-ARs decreases, and β2-ARs increases with increasing sensitivity to adrenergic toxicity  




Increasing cAMP promotes the phosphorylation of phospholamban (PLB).57  
Sarcoplasmic reticulum calcium ATPase2a (SERCA 2a) and PLB are proteins for 
calcium handling regulation inside the cardiomyocytes (Fig.1.6).  These proteins are 
involved in regulating the contraction-relaxation of the heart muscle.  Phosphorylated 
PLB enhances the activity of SERCA2a by increasing the affinity of Ca2+ on SERCA2a.  
This activated SERCA2a then transports calcium against the gradient from cytoplasm 
back to sarcoplasmic reticulum (SR) for muscle relaxation.58  Phosphorylated PLB 
(pPLB) releases this inhibitory effect, making the affinity site to Ca2+ on SERCA2a more 
apparent.  As a result, the rate of calcium ions influx back to the SR increases, promoting 
the muscle relaxation and being ready for the next contraction.   Without being 
phosphorylated, PLB binds to SERCA2a, preventing the Ca2+ binding to SERCA2a, and 
hence becoming an endogenous inhibitor of SERCA2a.    
                   
Figure 1.6: Simplified schematic of the biomechanical pathway relating to calcium 




Sarcomere length, a basic contractile unit of cardiomyocyte, can be affected by the 
mechanical stimulation.59  When the muscle is stretched to a length greater than normal 
size, new sarcomere units are added rapidly at the end of the muscle fibers.60, 61  Unlike 
the skeletal muscle, small changes in sarcomere length can result large changes in tension 
generation.59, 62, 63  Therefore, increasing the sarcomere length enhances the tension 
development, which affects the changes both in preload condition and the contractility of 
the heart.      
 
TnT and Alpha and Beta-Myosin Heavy Chain (α, β-MHC) are proteins involved in 
cardiac sarcomere function as discussed previously.  TnT is one of three troponins 
binding with tropomyosin.  TnT affects the function of thin filaments and the interaction 
between the thin and thick filaments, regulating cardiac muscle contractility.50 
Abnormality of this TnT gene can cause sudden death for cardiac patients. 45  
 
Myosin heavy chain (MHC) is a major protein expressed in heart tissue during the 
developmental stage and is responsible for mechanical performance of the heart, 
especially muscle contractility.64-66 In higher vertebrates, two cardiac isoforms of MHC 
predominate. β-MHC is expressed mainly during embryogenesis or heart diseases while 
α-MHC exists dominantly in the adult heart tissue and inhibits the expression of β-MHC.  
The temporal expression of α and β-MHC is species specific.  Interestingly,  the 




 In addition, the deformation of the cytoskeleton can change the physical properties of the 
cells and distort the nucleus, as well as the biochemical and molecular events inside the 
cell, such as gene expression, transcription, translation and protein synthesis.  This 
change also affects physical and chemical communication between cells.  Therefore, the 
structure inside the cell, morphology of cell, and the biochemical aspects of the cell are 
altered as a result of mechanical stimulus.   
 
To respond to any abnormal condition of mechanical stimulations, such as overpressure 
or overstretch, the heart begins to remodel itself.  The remodeling of the hearts causes an 
increase in the number of fibroblasts, thickens the heart muscle wall, or enlarges the size 
of the hearts.61, 68, 69  These changes play critical roles in contractility of the cardiac tissue.  
If the abnormal mechanical stimulus persists, heart remodelling can lead to the cardiac 
dysfunction (Fig. 1.7) 
 






1.5.   CONCLUSION 
The heart is the central organ within the cardiovascular system and is extremely complex 
in terms of construction and function.  This chapter serves to provide an overview of 
CVD and the heart structure and function.  CVD is a serious health problem and 
continues to claim millions of lives each year while also diminishing quality of life for 
several others.  However, current treatment options, though beneficial have several 
limitations.  In order to improve the quality of life, researchers therefore continue to 






IN-VITRO MODEL SYSTEMS TO STUDY CARDIAC TISSUE 
 
 
2.1.   NEED FOR CELLULAR-LEVEL STUDIES 
 
The human body consists of sequential levels of structural and functional organization. 
Cells are the smallest functional units capable of sustaining themselves and consist of 
various molecular constituents, including bio-molecules like DNA, RNA and proteins.  
Cells are organized together to form tissue.  Organs in the body responsible for 
specialized functions are made up of one or more types of tissues.  Various organs and/or 
tissues in the body are organized together to form systems (Ex: Cardiovascular, Nervous, 
or Circulatory).   Finally, an organism sustains life due to synergistic working of various 
systems within the body.  Several mechanisms exist to provide feedback and maintain the 
body’s functions within a tight range (homeostasis).  
 
The tradeoff between generations of highly specific molecular information and 
translation of that information in-vivo necessitates investigation at various levels of 
cellular organizations (Fig.2.1).  Cell-based studies are essential to provide highly 
specific information relating to molecular mediator and the targets for drug discovery, 
therapy, and tissue generation.  Analysis of purified or isolated cell populations free from 
surrounding cellular and extracellular constituents allows the investigation of sub-cellular 
mechanisms in great detail, which is not possible in intact tissues.70 Study of 
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heterogeneous mixtures of cells (like in a tissue) often results in unnecessary noise, which 
significantly deteriorates the quality of information attainable.    
       
     
Figure 2.1: Biologic complexity versus clinical translation plot. Human clinical studies 
are the most relevant, by definition, to clinical translation, but have the least specific 
whereas cellular level studies provide highly specific information but their relevance to 
human physiology is low.  The in vitro cell cellular model devices seek to significantly 
enhance the relevance of cellular level studies.   
 
Further, cellular level systems that utilize purified cells, allow for convenient analysis, 
using both destructive and non-destructive techniques.  Cells can be imaged using 
microscopy to study structure, conformation, the expression of intra and extra-cellular 
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markers, organization of organelles and other details of nuclear and cytoskeletal 
elements.  Low and high-throughput techniques can be used to evaluate gene expression, 
protein expression and production of metabolites.  The effect of a drug can be understood 
in terms of molecular signaling events that alter cell phenotype and function.  High-
throughput cell culture, using multi-well plates, can be used to evaluate effects of 
variables, including concentration of stimulants and time of exposure on cellular 
function.71  The flexibility and specificity of information generated from cellular level 
systems is unparalleled, and is usually an essential first step in any drug discovery study 
or tissue generation.  However, since cell-based studies use isolated cells in a non-
physiological environment without mechanisms responsible for homeostasis, the 
relevance of these studies is limited, and results need to be verified using animal and 
patient level studies.  
 
In-vitro studies are performed in isolation without the biologic complexity and the 
paracrine feedback mechanisms present in the body. Therefore, to understand the real and 
long term effects of a biochemical compound, foreign tissue, drug, or device on an organ 
or in a system, in-vivo evaluation is essential.  Animal studies are used to confirm 
outcomes before application in the human body.  Animals are similar in complexity to 
humans; and the levels of organization are conserved amongst most species.  Small 
animal studies, like study on rats, mice, hamsters and rabbits, are easier to perform due to 
cost related issues and availability of significant amounts of information and 
characterization of various systems in animals.61, 72  Further, technologies for generation 
of transgenic animals allows for greater flexibility with design of studies to evaluate 
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targeted pathways.73  Large animals are physiologically closer to humans and provide 
improved relevance due to greater similarities in size of organs and function of 
systems.74, 75 Large animals are particularly useful in testing organ/ tissue transplantation 
or implantable medical devices because the size of their organs is comparable to humans 
and provides a more accurate representation of the actual situation.  
 
Patient or clinical studies are often the last stage of evaluation for a particular drug or 
treatment.  This follows pre-clinical studies accomplished using in-vitro methods and in-
vivo animal studies.  Clinical trials allow assessing the safety and effectiveness of a new 
medicine or device on patients.  Clinical studies are divided into phases 0, 1, 2, 3, and 4.  
Phase 0 trial allows an early evaluation of the pharmacokinetic effects of the candidate 
drug in humans. This is done by administrating a low dose of the test compound in a 
short time period.  This phase 0 trial doesn’t have a therapeutic or treatment purpose; 
rather, allows the researchers to explore the pharmacological profile of the test compound 
in human to see if it is appropriate for humans or not.76   As a result, it helps to select the 
potential drug.  The disadvantage of this phase is the poor relation between the preclinical 
and clinical effect of the testing drug.77  Phase 1 is the first stage to test the dose effects 
on human subjects, so the appropriate dose of a certain drug on humans can be found.  
Phase 2 trials assess how well the drug works and continues to affirm the safety of the 
drug on large groups.  Phase 3 trials are applied on a huge group to see how effective the 
drug is for a certain type of disease.  And finally, phase 4 post-marketing surveillance 





In conclusion, cell-level studies are highly specific and can be used to investigate 
molecular mediators and signaling pathways involved in disease processes.  These studies 
cannot be accomplished in patients because of inherent difficulties with isolation of cells 
and analytical techniques.  Animals provide a more appropriate platform for early 
evaluation as they provide more opportunities for evaluation.  To shorten the time 
between discovery and clinical validation, it is essential that cell-based studies are 
accomplished in platforms that have physiological relevance.  For example: studying 
cardiac tissue under unloaded static conditions is undesirable since mechanical loading 
and fluid flow play an important role in maintaining cell structure and phenotype.  
 
2.2. IMPORTANT CONSIDERATIONS FOR CELL-LEVEL METHODS OF 
CARDIAC TISSUE DEVELOPLMENT AND CHARACTERIZTION 
During normal heart function, the myocardium experiences passive stretching and 
increasing transmural pressure during filling (preload) and actively generates mechanical 
force with further increase in wall stress during ejection (contraction).  Cells in cardiac 
tissue therefore are under constant physical stimulation and rely on the conversion of 
these cues into intracellular signals to control cell phenotype and muscle mass during 
physiologic and pathologic conditions.78  Cardiac cells therefore are exposed to periodic 
stress, strain, and shear. 
 
Physiological heart development and cardiac function rely on the response of cardiac 
tissue to mechanical stress signals during hemodynamic loading and unloading.  These 
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stresses manifest themselves via changes in cell structure, contractile function and gene 
expression.72 Disruption of this well-balanced stress-sensing machinery due to various 
pathological conditions results in mechanical dysregulation, cardiac tissue remodeling 
and heart failure.  To achieve physiological relevance, in-vitro models must replicate the 
complex, dynamic in-vivo interactions between cardiomyocytes and mechanical stress 
signals. However, current in-vitro models do not incorporate all aspects of mechanical 
loading and therefore fail to accurately mimic the in-vivo cardiac microenvironment. 
 
2.3.   REVIEW AND CURRENT STATE OF THE ART  
Several animal model studies have proved that hemodynamic mechanical stimulations 
play significant roles in shaping the formation and ensuring proper heart functions.19, 79-84 
Therefore, for cardiomyocyte differentiation into functional cardiac tissue, in-vitro 
mechanical stimulation should be included during in-vitro cardiac tissue regeneration.   
 
Various clinical studies for cardiac tissue regeneration via transplantation of progenitor or 
differentiated cell population have been established.85-87 However, the goal of tissue 
replacement with functional myocardium has not accomplished because a majority of 
studies apply the direct delivery of undifferentiated cardiac cells to the injured 
locations.88   In addition, the current state of cardiovascular in-vitro models is 
predominantly cultured under conventional static conditions.69, 70, 89  Most studies utilize 
isolated cardiomyocyte cells maintained in two-dimensional culture forming randomly 
oriented cell-extracellular matrix (ECM) interactions.73, 90, 91 Culturing cardiomyocytes in 
a 2D system does not reflect the physically biological environment that the in-vivo 
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cardiomyocytes experience. As a result, the phenotype and behavior of these 2D cultured 
cardiomyocytes appear differently from the cardiomyocytes in the in-vivo normal 
conditions.92   Cardiomyocyte grown on the 2D condition shows flattened, stellate-shape 
phenotype instead of a rod-shape phenotype as it is in the in-vivo environment.  
Proliferation rate, differentiation, and DNA synthesis are poor.16, 93, 94 The interaction 
between cell-cell or cell-matrix are limited due to the 2D planar geometry; thus, cell-cell 
connections are loose, which fails to initiate spontaneous contraction.  
 
There are groups using 3D engineered cardiac constructs to investigate cardiomyocyte 
maturation, response to drugs, and the effects of genetic defects in ion channels and 
sarcomeric proteins. The phenotype and molecular regulation and the function of 
cardiomyocytes in 3D shows more likely resemble the in-vivo cardiomycytes. 16, 92-100 
However, there are a limited number of bioreactors that can generate 3D tissue on a scale 
relevant for clinical translation.  Complex systems that can replicate in-vitro mechanical 
stimulation occurring in the heart are currently unavailable. Accurate replication of the 
in-vivo environment requires consideration of several factors.  First, tissue orientation and 
direction of stretch are critical determinants of cardiac cell signaling; therefore randomly 
oriented cultures cannot replicate physiological loading.  Second, fluid flow is an 
important factor as shear stress strongly influences endothelial and smooth muscle 
phenotype but not cardiomyocytes. Third, cyclic build-up of pressure and stretch during 
preloading are critical determinants that dictate cell structure and function; hence, 
perfused systems are more representative of the in-vivo environment.  Fourth, 
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synchronous contractions ensure ejection of fluid that in turn results in relaxation of built-
up pressure and stretch.38 
 
 
Some of the aforementioned issues have been previously addressed, albeit individually. 
Patterning techniques like micro-contact printing and lithography to define areas of cell 
attachment and directional alignment have been accomplished.101-103 Several groups have 
cultured cardiac cells under continuous and cyclic loading conditions to mimic in-vivo 
hemodynamic loading.104-107  Commercial technologies like  Flexercell® Strain -FX-4000 
Flexercell Tension Plus(TM) (http://www. flexcellint.com), which consists of a flexible 
membrane on which cardiac cells can be plated and then be subject to oscillatory 
deflections using a vacuum or pressure source, have been used to apply mechanical 
stretch.96, 108  Electrophysiological studies utilize systems such as the IonOptix Myocyte 
Systems (http://www.ionoptix.com) where cardiomyocytes grown on a glass slide are 
stimulated with an electrical impulse and analyzed for contractility.  However, to the best 
of our knowledge, no in-vitro system currently replicates all aspects of cardiac 
mechanical loading and unloading in the heart. 
  
2.4. PHYSIOLOGICALLY RELEVANT SYSTEMS FOR CARDIAC CELL 
CULTURE 
Various manifestations of cardiovascular diseases directly correspond to changes in 
mechanical behavior of cardiac cells.  This, in turn, affects cellular phenotype and 
function, causing changes like hypertrophy, growth of fibrous tissue, and establishment 
of random cellular orientation.69 For example, in hypertension, the pressure inside the 
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heart exceeds the normal range due to a high resistance in vascular system and eventually 
results in hemodynamic overloading of the heart and vasculature.  This higher 
intracardiac and transmural pressure triggers myocytes hypertrophy initially and 
subsequently can lead to a dilated phenotype associated with myocytes loss.  In the long 
term, this additional stretch weakens the heart muscle, causing heart failure.61 In the 
contrast, hypotension refers to the condition where the pressure inside the heart is lower 
than the normal range due to abnormal filling or ejection or where the arterial vasculature 
is abnormally dilated.  This causes reduced blood circulation and oxygen deprivation to 
the rest of the body.  In response to this oxygen deprivation and reduced nutrient 
delivery, the heart rate increases, resulting in altered stretch and pressure profiles.    
 
The frequency of the loading determines the ranges for normal and abnormal heart 
function.   For example, in human, bradycardia is a condition where the heart rate is 
lower than 60 bpm, and tachycardia is another condition characterized by a significantly 
higher heart rate (>200 bpm) in comparison to normal heart rate (~75 bpm).  In response 
to these abnormal patterns, the heart either lowers or increases the systolic fraction.109 All 
of these changes can cause the reorganization of cardiac tissue and it can lead to heart 
failure or sudden death if it persists long term.110 
 
Finally, due to fluid flow, shear stress can be a significant mechanical cue for cardiac 
endothelial and cardiac smooth muscle cells.  Cardiac endothelial cells contribute to the 
internal lining of the myocardium and are directly exposed to fluid induced shear stress 
during hemodynamic loading and unloading.  Changes in magnitude, frequency, or 
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duration of shear stress are crucial for the structure, function and permeability of 
endothelial cells.  Various clinical conditions occur as a result of changes to shear 
profiles seen by cardiac endothelial cells.  
 
Studying cardiovascular disease requires appropriate cellular level platforms which can 
be used to culture cells while accurately mimicking mechanical and fluidic loading 
conditions seen in-vivo.  In cardiovascular disease, various conditions are associated with 
distinct mechanical loading profiles and replication of those profiles is critical to ensure 
proper understanding at the cellular and molecular levels.  Mechanical loads experienced 
by cardiac cells vary as a consequence of dysfunction including pressure, stretch and 
shear stress, as well as the frequency and duration.  
 
2.5. IN-VITRO TECHNIQUES FOR MECHANICAL STIMULATION OF CELLS 
Cells in different tissues experience cyclic compressive loads.  Cardiac and vascular 
tissues are examples of tissue where cells within the tissue are constantly under 
compressive loading.  Replicating this condition in-vitro can be accomplished using 
different techniques such as application gas pressure (hydrostatic compression) directly to 
the culture system or through the fluid induced loading of the system (pressure loading). 
These techniques cause direct application of pressure to cells in culture mimicking 
conditions seen in-vivo. 
 
Another commonly seen loading condition in cardiac and vascular tissue is cyclic stretch 
(and strain).  The most common approach to stretch the cells in culture is by growing the 
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cell on a flexible surface and applying stretch on the surface where the cells are attached.  
The stretch can be uniaxial, biaxial, and include shear.  With the uniaxial stretch, the 
surface is either rectangular or square and is stretched in one direction either 
longitudinally to both ends, or is bent/flexed in a four-point bending.  With the biaxial 
stretch, the membrane is circular and the edge of the membrane is fixed.  The applied 
pressure deforms the membrane in both the radial and circumferential directions.  
However, the strain depends heavily on the location on the membrane, causing the cells 
on different locations to stretch differently.  For example, cells seeded at the center will 
stretch more than those at the edges.  As a result, it is extremely complicated to analyze 
the data and to interpret the cells behavior.  To produce the equi-biaxial strain, the 
membrane has to slide non-frictionally on a stable plane.  On this plane, the stress 
distribution on the area of the membrane where it is supported by the plane, is 
symmetrical, creating an isotropic and spatially constant strain. 
 
Finally, cells in different tissues experience shear stress as a consequence of fluid flow.  
Shear stress is a key mediator of cells phenotype.  Shear stress controls alignment and 
establishes cell-cell contacts, which are important in the formation of tight junctions in 
ensuring low permeability in vasculature.  The velocity, as well as the pattern of the flow, 
laminar versus turbulent flow for example, can create different shear stress on the cells.  





In cardiac and vascular tissue, all three of these loads (cyclic pressure, stretch, and shear 
stress) are experienced simultaneously. Additionally, changes in one or more of these 
loads have a cascading effect on the entire system.  Therefore in-vitro models of cardiac 
tissue need to mimic accurately the combined effects of cyclic pressure, stretch and shear 
in a pulsatile fashion.  
 
2.6. CONCLUSION 
Based on the discussion above, due to the complex nature of the heart and the importance 
of mechanical loads, an in-vitro cellular culture model designed with physiological 
relevance is critical to investigate the cellular and molecular adaption of cardiac cells and 
tissues relevant to cardiovascular adaption and disease.   No device or cell culture 
platform is commercially available today to accomplish long term culture of cardiac cells 
in-vitro with accurate replication of realistic mechanical loading profiles.  Efforts by 
other groups thus far have succeeded in replicating isolated mechanical loads.  There is 
still a need for platforms where the culture conditions can be dynamically varied not only 
to replicate normal loading conditions, but also abnormal loading conditions.  These 
platforms are necessary to study the molecular pathophysiology of cardiovascular 









Understanding the molecular basis of manifestations of cardiovascular disease requires 
multiscale and multilevel approaches and an appreciation of the developmental 
mechanisms that regulate cardiac morphogenesis and remodeling.  Because 
cardiomyocyte cell death is the major cause of cardiac pathology leading to heart failure, 
many efforts are underway to restore cardiac tissue structure and function through 
regenerative approaches.69  Unfortunately, unlike most cells in the body, cardiomyocytes 
stop differentiation and have limited proliferative potential after birth in higher 
vertebrates.101  To accommodate, scar tissue replaces the damaged cardiac tissue. Scar 
tissue increases the stiffness of the heart tissue and cause the inability to regenerate the 
same contractile forces as the normal undamaged cardiac tissue does. Therefore, cardiac 
tissue engineering plays a significant role in the process to find better treatment of heart 
disease due to the loss of cardiomyocytes.  However, replicating all aspects of the 
mechanical loading and unloading environment for the in-vitro cardiac cultured cells is a 
challenging task as discussed in chapter 2. It is because the myocardium experiences 
passive stretching and pressure build-up during filling (preload) and actively generates 
mechanical force during ejection (contraction) against variable afterload.  Cells in cardiac 
tissue are under constant physical stimulation and rely on conversion of these cues into 
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intracellular signals to control cell phenotype and muscle mass during mechanical 
conditions. Therefore, to study the molecular pathophysiology of cardiovascular diseases, 
in the discovery of drugs, treatment options, and cardiac cell regeneration strategies, in-
vitro cardiac tissue must be cultured in the in-vivo like environment.  
The need for platforms where the culture conditions can mimic the physiologically 
mechanical condition and can be dynamically varied to normal and abnormal 
environments necessitates engineers to design different cell culture models. With a 
primary goal of  replicating such in vivo mechanical loading conditions for in-vitro 
cardiomyocytes and to enable cardiac tissue generation, a microfluidic cardiac cell 
culture model (µCCCM) was developed.111  The first generation of the cardiac cell 
culture model was built in 2008 in order to mimic cyclic mechanical strains and pressures 
experienced by cells during the cardiac cycle.  With this model, cardiac cells undergo 
cyclic stretch and contraction, pulsatile pressure, as well as fluid loaded and ejected.   
 
3.2. THE µCCCM 
The µCCCM system consists of a peristaltic pump, cell culture chamber, pulsatile 
actuated collapsible valve, and a tunable resistance in a series, along with accessories 
including tubing, an oil chamber, a pressure generator, and a digital manometer. (Fig. 
3.1)  
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Figure 3.1: Assembled µCCCM for cell culture experiment.  The tunable valve and 
collapsible valve were placed downstream of the cell culture platform to create the 
resistance and pulsatile pressure inside the cell chamber. Cell culture chamber (pink 
color) was clamped between two fixtures of the cell culture platform.  The µCCCM 
system has a closed circulating fluid network. 
  
Cells were placed in culture on a thin PDMS membrane attached at the bottom of the cell 
culture chamber inside the platform. Continuous circulation of culture medium is 
maintained using a peristaltic pump.  Downstream the chamber is a collapsible valve 
actuated in a pulsatile fashion using a pressure generator.  Closure of this collapsible 
valve leads to pressure build up in the chamber, which in turn also leads to stretching of 
the thin membrane as well as the cells on this membrane.  This stretching phase mimics 
the diastolic loading phase in the ventricle.  To ensure uniformity, a post is placed 
beneath the thin membrane such that, during stretch, the portion of the membrane on 
which cells are cultured experiences uniform strain and the edges experience larger non-
uniform strain (Fig. 3.2). Lubricating oil fills in the chamber beneath the cell culture area 
to create friction-free sliding of the membrane on the post.  Further, to influence outflow 
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resistance, a tunable homeostasis valve is placed downstream of the collapsible valve to 
mimic afterload.  Fluid transport and subsequent shear stress can be controlled by varying 
the pump flow rate.  Pressure buildup and strain can be controlled via a combination of 
factors, including the thickness of the membrane, fluid flow rate, and operation of both 
valves  
                      
Figure 3.2:  Setup design for equi-baxial strain. A significant deformation at the edges of 
the membrane occurs when the pressure is applied, but the area of the membrane rested 




3. 3.   FABRICATION AND ASSEMBLY OF THE µCCCM 
3.3.1. Assembly for Housing the Cell Culture Platform and the µCCCM 
components 
The assembly for housing the cell culture platform was fabricated in the Rapid 
Prototyping Facility at the University of Louisville using Computer Numerical Control 
(CNC) Milling Machine.  The designs were laid out using Solidworks 3D layout software 
prior to machining the assembly using CNC milling.  Acrylic was used for construction. 
(Fig. 3.3)  
               
            
Figure 3.3: Schematic representation of the top and bottom fixtures of the platform for 
housing the cell culture chamber.  [A] The top fixture has the fluid inlet and outlet 





The cell culture chamber (~1cm diameter) and oil chamber were made from polydimethyl 
siloxane (PDMS) (Dow Corning, ratio 1:10 of the curing agent and the base) using 
standard soft-lithography techniques.  The collapsible valve was created mainly via thin 
elastic ARGYLE Penrose tubing. More detail information for these fabrications will be 
seen in the published article.111 
 
3.3.2. Assembly of the µCCCM 
First, an acrylic sheet was placed in the rectangular hole on the bottom piece of the 
platform, followed by the oil chamber (Fig.3.4).   Then, the cell culture chamber, with 
18G needle inserted, was aligned on top of the oil chamber. The top piece of the platform 
was then laid on top of the cell chamber.  The platforms were tightened with four screws.  
Finally, low viscosity oil was injected into the oil chamber through needles. 
 
 A 3-stop Pharmed BPT tube (1.3 mm ID, Cole-Parmer, Vernon Hills, IL) was connected 
from a 50 mL medium container to the inlet of the device via a peristaltic pump (Ismatex, 
ISM 596D, Vancouver, MA).   The collapsible valve was connected from the outlet of the 
device to the medium container.  The tunable valve was placed downstream of the 
collapsible valve (Fig.3.1.). Finally, the pressure sensor was connected to the needle, 
which was connected to the cell chamber.  A pulsatile pressure generator was connected 




                   
Figure 3.4:  Assembly of the cell culture and oil chambers between the platforms. 
 
3.4. OPERATION OF THE µCCCM  
 
Once assembled as in Fig. 3.1, the peristaltic pump was started gradually from a low flow 
rate to the desired flow rate.  After 30 min running, the pressure in the pneumatic 
pressure generator source was applied and the tunable valve was adjusted until the 
pressure reached the desirable values.  Variable parameters, such as the frequency of the 
membrane stretching as well as the percentage of systolic phase per one cycle, were 
determined based on the requirement of each experiment.  The frequency of the 
stretching was controlled through the % systolic and the frequency controls on the 
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pressure generator source.  The pressure inside the cell chamber was varied by the 
corroboration between the pressure applied on the collapsible valve and the adjustment of 
the tunable valve.  The stretching level of the membrane was determined by the thickness 
of the membrane, which were measured and standardized appropriately and the pressure 
applied on the membrane.  And the shear stress on the cells was controlled by the 
velocity of the fluid loading and the dimension of the cell culture chamber.   
 
3.5. APPLICATIONS 
3.5.1. Pressure profiles 
The device was assembled and the pressure build-up within the chamber was generated 
for the following clinically relevant experimental conditions – normal, heart failure, 
hypertension, hypotension, tachycardia, and bradycardia. To accomplish pressure 
monitoring within the chamber, a high-fidelity pressure catheter (Millar Instruments, 
Boston, MA) was inserted through a hemostatic valve and syringe needle such that the 
pressure sensing element resided in the center of the chamber.  The chamber pressure 
waveforms were analyzed by using a Hemodynamic Evaluation and Assessment 
Research Tool program developed in Matlab (MathWorks, Natick).  The different 
waveforms for various physical heart conditions were therefore replicated and recorded 
by either increasing or decreasing the pressure in the pressure generator and by adjusting 
the tunable valve (Fig. 3.5). These results confirmed that the µCCCM enabled to 




           
Figure 3.5: Pressure waveforms that simulate various physiologic conditions in the 
µCCCM.  These conditions include both normal and dysfunctional myocardium, such as 






3.5.2. Cell studies for the proof-of concept 
H9C2 cells were cultured within the µCCCM system to demonstrate the proof-of-concept. 
H9C2 cells were cultured in static condition (control) and within the μCCCM under 
pulsatile pressure and stretch, representing normal physiological loading (peak pressures 
of 120 mm of Hg, strain of 20% and a frequency of 80 bpm with 50% systolic to 
diastolic, flow rate of 8.4ml/min) for 24 h at 37oC and 5% CO2.  More detail of cell 
culturing is available on the published article. 111 
 
The results showed that cells not only survived physiological loads but also showed the 
positive effects of physiological loading.  Cells cultured in static condition (control) 
attained a fibroblast like morphology (Fig. 3.6a), whereas cells cultured in the μCCCM 
were more rectangular, and presented a postage stamp-like morphology (Fig. 3.6b). The 
size of the cells cultured within the μCCCM exposed to pressure was larger than those 
cultures in static condition.  
 
Staining with Phaloidin showed a low intensity fluorescent color and random orientation 
of f-actin in controls in comparison to aligned f-actin in cells cultured with pulsatile 
pressure and stretch (Fig.3.6c and d). This indicated that the contraction-stretching of the 
cells promotes the increasing % of f-actin and also an increase in the length of the 
sarcomere, and helps to align the cells in one direction. The increase in the length of the 
sarcomere is the result of the increase in contraction of the cell under pulsatile stretch. 
The alignment of the cells demonstrated that mechanical loading spontaneously 
rearranged the orientation of the cells.  
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P-phospholamban was detected in cells cultured within the μCCCM, however, the 
expression of this protein was very low in cells cultured in static condition, as shown is 
Figure 3.6e, in comparison to the cells cultured in μCCCM (Fig. 3.6). Phospholamban is 
the integral membrane protein. To respond to the contraction of the cells, phospholamban 
is phosphorylated. With cAMP, this p-phospholamban promotes the influx of Ca2+ into 
the cells to bind to the contractile unit, causing the cells to contract.112, 113 Therefore, 
indirectly, the increasing of activation of p-phospholamban, which was reflected by the 
intensive green color on the loading sample, in comparison of the color on the control 
sample on the Fig. 3.5.e and f, will be indicative of cell contraction. 
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Figure 3.6: Physiological loading promoted the alignment of f-actin and increased 
phosphorylated phospholamban activity in H9C2 cells.  Cells were under a static 
condition (control) and normal physiological loading for 24 hrs. Notice the directional 
alignment of f-actin stress fibers and increased p-phospholamban activity in the loading 
condition. (a, b) Phase contrast images; (c, d) Staining with TRITC-conjugated Phaloidin 
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for detection of f-actin; (e, f) Immunofluorescence staining for detection of p-
phospholamban activity; (g, h) Merged images of F-actin and p-phospholamban.  
 
The proof-of-concept demonstrations using the µCCCM system for cardiac culture were 
accomplished, confirming that this system has the ability for the design and study of 
various conditions with different cell types associated with CVD.  These studies can be 
cardiomyocyte regeneration using mechanical loading and stem cells, adult 
cardiomyocyte regeneration using controlled mechanical loads, study of cardiac and 
aortic endothelial cells under conditions of continuous and pulsatile flow 114, 115 and 
finally, evaluation of drugs and other treatment options using cardiac cells maintained 
under various disease conditions.  
 
3.6. CONCLUSION AND LIMITATIONS 
Microfluidics based systems have been used to create cardiomyocyte actuators and 
pumps as well as cell models.102, 116-121  The µCCCM was the first system, to our 
knowledge, that was developed to replicate the mechanical loading conditions observed 
in the heart, which includes the fluid flow, pulsatile stretch, and pressure.  The µCCCM 
allowed dynamic studies accomplished via the direct manipulation of flow rate, valve 
operation, membrane thickness and the height of the cell culture chamber.  We 
envisioned that this system would provide time varying mechanical cues for 
differentiation of stem/progenitor cells into adult cardiomyocytes and would also provide 
mechanical conditioning to generate sufficient contractile forces and integrate within 
native cardiac tissue to augment cardiac function. However, after re-examining carefully 
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the working principles of this system, we recognized that the pressure-volume 
relationships seen this in vitro system did not accurate replicate in vivo left ventricle PV 
relations.  First, in-vivo, the stretch of nature cardiac tissue is mainly due to the fluid 
loading during the loading phase, while the stretch of the PDMS membrane in the 
µCCCM is based on the pressure generated inside the cell chamber during the loading 
phase.  Second, the stretch and contract of cardiomyocytes are in 3D directions, which 
include circumferential and radical stretch.  With the post, this µCCCM system creates 
the 2D biaxial stretching.   In addition, in this model, the cells were seeded on a rigid 2D 
surface membrane which potentially constrained cell shortening and does not reflect the 
physiological condition of the in-vivo tissue.   The summaries of similarities and 
differences between the left ventricle and the µCCCM system are listed on the table 3.1.  
To overcome these shortcomings, the second generation of the cardiac cell culture model 
(CCCM) was designed and developed.  In this new system, cells were cultured on a soft 
matrix attached to the top of a thin PDMS membrane in a cell culture chamber.  With 
each cycle, cells cultured within the CCCM underwent passive stretch, isovolumic 
contraction and pressure buildup, ejection and relaxation.   Thus, the second generation of 
cardiac cell culture model system is essentially a left ventricle mimic that can be 
dynamically tuned to go from static unloaded state (as seen in very early development), 








Table 3.1: Summary of similarities and differences (in italic) between the left ventricle 
and the µCCCM system 
Aspects Left Ventricle 
 
The µCCCM system 
Working 
principles 
- “Filling” phase: fluid in, no 
fluid out, no pressure buildup. 
 
- Isovolumic contraction phase: 
pressure inside is compressed, 
no fluid in nor out.  
 
- Ejecting phase: cavity pressure 
exceeds aortic pressure, 
pressure peaks and then begins 
to decline. 
 
- Isovolumic relaxation phase: 
muscle relaxes and pressure 
decreases prior to the next 
filling cycle.  
 
 
- “Stretching” phase: fluid in, no 
fluid out, low pressure buildup. 
  
- Contracting phase: pressure 
inside is released, fluid in and 
out. 
 
- Ejecting phase: the releasing of 
the collapsible valve- pressure 
inside released and goes down. 
 
 




- One way valves at the entrance 
and outlet of the ventricle 
- Only one collapsible valve 
downstream of the chamber, 
and the fluid continuously 
loaded to the cell chamber.  
-  
Stretching - 3 dimensional strains 
 
- Biaxial stretch 
Cell 
cultured 







THE SECOND GENERATION CCCM SYSTEM 
 
4.1. COMPONENTS OF THE SECOND GENERATION CCCM SYSTEM 
The Second Generation CCCM system consists of a fluidic flow pathway, an air 
pathway, a cell culture platform station,  and a control system (Fig. 4.1).122  
 
The fluid flow network includes a medium reservoir, a peristaltic pump, a fluid 
compliance, an upstream one-way valve, a cell culture platform station, a downstream 
one-way valve, and a tunable pressure relief valve in a series (Fig.4.1).  From the medium 
reservoir, via the assistance of the pump, the fluid flows through the upstream one-way 
valve into the cell culture chamber and exits the cell culture chamber.  The fluid then 
passes through the downstream one-way valve and the tunable valve and then returns 
back to the reservoir before being recycled within this flow loop via the peristaltic pump.  
A bypass with a spring valve was installed at the downstream pathway to prevent the 
chamber pressure from exceeding the pressure range set up for each case of studies.   
 
While the fluid network is a closed pathway, the air network is a partially closed 
pathway.  The air network includes the cell culture platform station, an air-compliance, a 
pneumatic valve, and a pneumatic pressure driver (Fig. 4.1).  Air from the driver enters 
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the cell culture platform station and passes through the air compliance and the pneumatic 
valve before returning to the pneumatic pressure driver.    This air network is a partial 
closed network because the pneumatic valve is a three-way valve.  One of its three ports 
releases air to the outside when needed.  
                
                                        
Figure 4.1:  A schematic image of the second generation CCCM system. [A] 2 pathways 


































where (a) the peristaltic pump, (b) upstream one-way valve, (c) the CCCM platform with 
cell culture chamber (arrow) and (d) the downstream one- way valve. 
 
The cell culture platform station includes a cell culture chamber, an oil chamber, and the 
housing station (Fig. 4.2).  The cell culture and oil chambers are placed on top of each 
other and in between the top and bottom plates of the housing station. Cells are cultured 
on a thin flexible PDMS membrane, which forms the base of the cell culture chamber and 
is thus sandwiched between the cell culture and oil chambers. This cell culture membrane 
deforms as fluid is loaded and unloaded to the chamber, applying cyclic stretch and 
relaxation to the cells. Underneath of the oil chamber is a post membrane. Therefore, the 
cell culture system is a chamber-membrane-chamber-membrane stack (Fig. 4.2.C).  The 
oil chamber transfers the displacement between the cell culture membrane and the post 
membrane (Fig. 4.2.E). The post membrane prevents the cell culture membrane from 
moving beyond its original position when the pneumatic pressure is applied on the other 
side of the post membrane (Fig. 4.2F).  Finally, the housing station has top and bottom 
plates to sandwich the cell culture and oil chambers and to install the fluid and air 
networks. The top plate of the housing station has an inlet and outlet ports for fluid 
loaded and unloaded to the cell culture chamber while the bottom plate has the inlet and 









Figure 4.2: Scheme of the CCCM cell culture platform station.   [A]: the housing station 
has (a) top plate with fluid inlet (solid arrow) and outlet (breakdown arrow) and (b) 
bottom plate with air inlet (solid arrow) and outlet (breakdown arrow).  [B]: the 
assembled CCCM chambers.  The assembled CCCM is sandwiched between plates of the 
station. [C]: the components of the assembled CCCM chambers: (i) cell culture chamber, 
(i) a flexible membrane where the cells are seeded (blue), (iii) oil chamber, and (iv) the 
post membrane. The assembled CCCM system is a chamber-membrane-chamber-
membrane stack. [D] Side view of the CCCM cell culture station: (i) top plate with fluid 
inlet (solid arrow) and outlet (breakdown arrow); (ii) cell culture chamber; (iii) cell 
membrane (orange); (iv) oil chamber made by 3 components (top, middle, and 
bottom)and  filled with oil, and (v) the post membrane (black color) bottom plate with air 






inlet and outlet. [E] The scheme of membrane deformed when fluid is loaded to the cell 
chamber.  This case, oil in the oil chamber transfers the displacement between the cell 
culture membrane and the post membrane, pushing the post membrane down (breakdown 
bar).   [F] Cell membrane goes back to its original position when the pneumatic pressure 
is applied on the other side of the post membrane. Due to the block from the bottom 
component of the oil chamber, the post membrane cannot move up further than its 
original position, preventing the cell culture membrane from moving beyond its original 
position.   
 
Fluid flows into the cell chamber, deforming the membrane downward.  The pressure 
driver provides cyclic pressure on the other side of the post membrane, pushing the 
deformed polymer membrane back to its original position.  Releasing this pressure 
stretches down the cell culture membrane during the fluid loading phase (Fig. 4.3). The 
frequency of this pressure as well as the percentage of loaded and unloaded time per each 
cycle is controlled by the program set in the pressure driver.   
    
                                
Figure 4.3:  Scheme of the PDMS membrane deflection under the influence of fluid and 
pneumatic pressure loading and unloading. [1, lower left] PDMS membrane in the phase 
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where no fluid filled into the cell culture chamber, the membrane has a horizontal 
position with no stretch.  [2, lower right] the membrane deforms downward when fluid 
flows into the chamber from above (arrows down), [3, upper right] the membrane is 
pushed back to its original horizontal position when outside pressure applied to the 
inferior side of the post membrane, pushing the cell membrane up (arrows up); and [4, 
upper left] after ejection occurs the membrane is returned to its original position and one 
cycle of stretching-relaxing is completed. 
 
The volume of the fluid loaded to the cell chamber is controlled by the peristaltic pump.  
Cyclic pressure inside the cell culture chamber is generated via the tunable pressure 
release valve and the pneumatic pressure inserted on the other side of the post membrane.  
The frequency and the air pressure loaded and unloaded to the station are controlled by 
the pressure generator.  Finally, a pressure sensor connected to the cell culture chamber is 
monitored via real-time LabView program; and the pressure waveform inside the cell 
culture is hence recorded (Fig.4.4).  
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Figure 4.4:  Image of the CCCM system connected to the LabView control system via 
pressure sensor.  
 
4.2.  DESIGN AND FABRICATION OF DIFFERENT COMPONENTS OF THE 
CCCM SYSTEM 
4.2.1. Design the Top and Bottom Plates of Cell Culture Housing Station 
 
The cell culture station was made in the Rapid Prototyping Facility at the University of 
Louisville using the Computer Numerical Control (CNC) Milling Machine.  The designs 
were laid out using SolidWorks software prior to machining the assembly using CNC 
milling.  Acrylic was the material used for construction.  
  
This station consists of the top and bottom rectangular plates (10.5 cm x 9.0 cm x 1.3 cm) 
(Fig. 4.5).  Two channels in the top plate serve as the entry and exit ports for fluid 
loading and unloading to the cell culture chamber.  The distance between two inner ends 
of these channels is 0.6cm.  The bottom plate of the platform has a circular hole (d =1.6 
cm, h = 1.0 cm) at the center and 2 horizontal passages from the center hole to the outside 
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edges (l = 4.6 cm, d = 0.4 cm), creating the inlet and outlet air channels.   Finally, 4 holes 













Figure 4.5: Schematic of the top and bottom plates of the station for housing the cell 
culture chamber.  [A] the top plate of the platform with entry and exit ports for fluid 
loading and unloading; and [B] the bottom plate of the platform with a circular hole at the 
center and two horizontal passages for pneumatic pressure pathway. 
 
4.2.2. Fabrication of the thin PDMS membrane 
The thin PDMS membrane was made from Sylgard®184 polydimethyl siloxane (PDMS) 
(Dow Corning, Midland, MI) using standard soft-lithography techniques. First of all, a 
mixture of silicon elastomeric base with its curing agent (ratio 10:1) was well mixed, 





Entry and exit ports 
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process.   To make a thin PDMS membrane less than 400µm thick, spinning method was 
used and the thickness of the membrane was determined by the spinning speed and time 
(Fig. 4.6). The degassed PDMS mixture was poured on a non-oxidized silicon wafer 
(0.525 mm thick, 100 mm diameter, Silicon Valley Microelectronics, Inc. Santa Clara, 
CA) and spun at a desire speed for 30 sec on a Headway Spinner (Brewer Science, Inc.,  
Rolla, MO).  The PDMS coated wafer was then baked at 90oC in an oven (Fisher 
Isotemp, Florence, KY) for at least 1 h.  Once the PDMS was cured, the wafer was 
removed from the incubator.  This method was used to make the post membrane. 
 
Figure 4.6:  Graph of PDMS membrane thickness (µm) versus spinning speed (rpm).  
The spinning time is 30 sec.  The membrane thickness as a function of spinning speed 
can be estimated using the equation y= 130728 x-1.05. 
 
For the PDMS membrane thicker than 400µm, gasket method was used.  Basically, the 
degased PDMS was poured to a square gasket (13.0 cm x 13.0 cm outside and 12.0 cm x 
y = 130728x-1.05 




















Spinning Speed (rpm)  
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12.0 cm inside) sitting on a square glass (13.0 cm x 13.0 cm).  The thickness of the gasket 
determines the membrane thickness.  A thin transparent plastic sheet was then slowly 
placed on top of the PDMS mixture followed by another square glass.  The whole setup 
was clamped tightly with paper clips and was put in the 90oC oven (Fisher Isotemp, 
Florence, KY) for being cured overnight to form a thin PDMS sheet (Fig. 4.7.). This 
method was applied to create the PDMS membrane at the bottom of cell culture chamber. 
                                            




4.2.3. Cell culture chamber and medium reservoir 
For the cell culture chamber, the degassed PDMS mixture (10:1 ratio) was poured in a 
mold until it reached 1.0 cm high.  After being cured at 90oC in the oven, the molded 
PDMS was removed from the container and a square piece of PDMS (3.0 cm x 3.0 cm x 
1.0 cm) was cut (Fig. 4.8).  A hole (d = 1.4 cm) was punched at the center of this PDMS 
piece using a cork borer.  Finally, a thin PDMS cell membrane, which was previously 
made, was placed at the bottom of this PDMS to form the cell culture chamber.    
 
To provide medium for cells cultured before placing them to the CCCM system, a 
medium reservoir was also created.  A hollow PDMS square piece (2.5 cm x 2.5 cm 
outside and 2.0 cm x 2.0 cm inside) was cut from the molded PDMS (Fig.4.8).  This 
reservoir was then placed on top of the cell culture chamber before sterilization.     
 




To measure the pressure inside the cell culture chamber, an accessible pressure chamber 
was created.  The molded PDMS slack was cut (3cm x3 cm) and a center hole was 
punched, similar to the cell culture chamber.  A horizontal channel was then created from 
the center hole to the edge via an 18 gauge blunt syringe needle (SmallParts, NE181PL-
C).  Finally, a 24 gauge blunt syringe needle (SmallParts) was inserted to this horizontal 
channel, served as a connecting port for the pressure sensor (Fig. 4.9.).  
 
Figure 4.9: Schematic representation of fabrication steps involved in construction of the 





4.2.4. Oil chamber  
The oil chamber was built in a mechanical shop Facility at the University of Louisville.  
Three square acrylic pieces were cut and a circular hole was grilled at the center of each 
piece. The dimensions of each squares acrylic pieces were in the table 4.1 below.  The 
edges of these pieces were smoothed before these pieces were glued together respectively 
to form the oil chamber. (Fig. 4.10, left) 
 
Table 4.1: Dimensions of each component of the oil chamber 
 
Components Thickness Square dimensions 
 
Hole diameter 
Top component (i) 0.3 cm 
 
4.0 cm x 4.0 cm 1.3 cm 
Middle component (ii) 1.0 cm 
 
4.0 cm x 4.0 cm 2.5 cm 
Bottom component (iii) 0.3 cm 
 





                    
 
                        [B] 
 
Figure 4.10: Schematic images of the oil chamber. [A] The oil chamber (top) and the 
post membrane (bottom). [B] Side view of the oil chamber: top component (i), middle 
component (ii), bottom component (iii) and the post membrane (black).  Oil chamber is 
filled with oil.  PDMS cell culture membrane (dark blue) is placed directly on the top of 






4.2.5. Fabrication of the post membrane 
A thin 400 µm PDMS (4.0 cm x 4.0 cm) previously made on a silicon wafer was peeled 
off.  This thin PDMS membrane and a circular glass (d = 2.5 cm, t = 0.25 cm) were 
exposed to 10% oxygen plasma for 30 sec in a reactive ion etcher system (RIE March 
Instruments) with 150 mmTorr and 150 mmHg.  The membrane and circular glass were 
then bonded together centrically and irreversibly to form the post membrane (Fig.4.11.).   
Finally, the subject was heated at 115oC on a hotplate (Standard Model 1100 Hotplate, 
Brewer Science, Inc., Rolla, MO) for 10 min to enhance the quality of bonding.   
                               
Figure 4.11:  Schematic representation of fabrication steps involved in construction of 





Cell culture chamber 
with pressure chamber  
Oil chamber with 
the post membrane 
Bottom 
component  
4.3.  ASSEMBLY OF THE WHOLE CCCM SYSTEM 
4.3.1. Assembly of the cell culture platform 
The cell culture platform was assembled in a sandwich style.  In general, the post 
membrane, oil chamber, cell culture chamber, and pressure chamber were stacked on top 
of each other respectively and clamped between two fixtures of the apparatus.  In detail, 
first of all, the oil chamber was firmly laid on the top of the post membrane to form a 
unit; and oil was used to fill this oil chamber.  Secondly, after the reservoir on the top of 
cell chamber was removed, the accessible pressure chamber was placed on top of the cell 
culture chamber to form cell chamber unit.  This unit was then placed centrically on top 
of the oil chamber without creating air bubble inside the oil chamber.   Thirdly, these 
stacked membranes-chambers were placed on top of the bottom component followed by 
the top fixture.  Finally, screws were used to tighten the components. (Fig. 4.12)  
 
 
             
Figure 4.12:  Side view of the whole assembled CCCM platform. 
 
4.3.2. Connection of the cell culture platform to the CCCM system 
The assembled cardiac culture platform was then connected to the flow loop and cyclic 
pressure network as shown on Fig. 4.2.  First, a 50 mL tube served as the medium 
reservoir to supply fluid to the cell chamber and to receive fluid flowing back from the 
cell culture chamber via a peristaltic pump, ensuring a continuous supply.  Fluid 
compliance and a one-way valve were connected to the upstream of the fluid flow 
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network.  A one-way downstream valve, tunable valve, and a by-pass pathway with a 
pressure gate valve were installed at the down-stream of this flow loop.  Flexible, 
autoclave compatible polymeric tubing was used to establish connections within the flow 
loop (Fig.4.13).  Second, the pressure sensor was attached to the cell culture chamber via 
the needle port of the pressure chamber.  Third, the air compliance was attached to the 
apparatus.   
 
This whole set up was then moved to the incubator before the pneumatic pathway was 
connected to the platform.  Once in the incubator, the air compliance was connected to 
downstream of the pneumatic pathway, while upstream of the airway was hooded to a 
pulsatile pneumatic pump (lb Engineering GbR).  Finally, the pressure sensor was 
connected to the computer; and the pressure inside the cell culture chamber was 
transferred digitally to the LabView Program on the computer.   
 
 
Figure 4.13:  Picture of the CCCM experimental setup. 
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4.4.  WORKING PRINCIPLES OF THE CCCM SYSTEM 
The working cycle of the CCCM mimics the working cycle of the left ventricle (Fig. 
4.14).  In the filling phase, fluid flow is introduced continuously into the CCCM cell 
culture chamber via the peristaltic pump.  Fluid fills the cell culture chamber causing the 
PDMS membrane to stretch passively.  The stretching of the membrane maintains the 
pressure inside the cell culture chamber as low as the base pressure should be.  This 
stretching phase mimics the left ventricular diastolic filling.  During the isovolumic 
contracting phase, air pressure generated by the pulsatile pneumatic pump (the frequency 
and pressure are programed based on each specific experiment) is applied to the reverse 
side of the post membrane, pushing the PDMS cell membrane back to its original 
position.   Pressure is thus built up rapidly within the cell culture chamber, causing the 
upstream one-way valve to close.  Because of this valve closure, the fluid from the 
peristaltic pump begins to be stored in the fluid compliance.  However, the cell chamber 
pressure at this point is not high enough to overcome the downstream resistance, 
therefore, no fluid is loaded or unloaded to the chamber.  This phase is similar to the 
isometric contracting phase inside the left ventricle.  For the ejecting phase, the pressure 
inside the cell chamber increasing until it exceeds the set value of the resistance to open 
the downstream valve and then the accumulated fluid loaded in the cell culture is ejected.   
Finally, the pressure applied to the reverse side of the membrane is released, causing the 
CCCM to undergo isovolumic relaxation before another cycle begins.  This phase mimics 






Figure 4.14:  A working cycle of the CCCM system and the pressure-volume loop 
occurred in left ventricle of the heart. [A] Schematic working principles of the CCCM 
system, including stretching phase (fluid loading causes the membrane stretched down), 
contracting phase (pneumatic pressure applied to the other side of the membrane brings 
the membrane back to the original position and elevates the chamber pressure), ejecting 
phase (chamber pressure overcomes the downstream resistance to eject the fluid out of 
the chamber), and the relaxing phase (no fluid in or out). X: valve is closed; : fluid 
direction.   [B] Pressure-Volume loop seen in the left ventricle:  (a) diastolic filling phase, 
(b) isovolumic contraction phase, (c) ejecting phase, and (d) isovolumic relaxation phase. 
 
Additionally, a programmable pressure generator is used to supply periodic pulses of 
pressurized air to the reverse side of the polymeric membrane on which cells are cultured 
to mimic ventricular contraction.  Finally two tunable compliance elements, a fluidic 
compliance integrated prior to the upstream one-way valve, and air compliance element 
integrated at the end of the pressure generator flow path, are used to modulate pressure 




pump, the frequency of the stretching-contracting of the PDMS cell culture membrane is 
controlled; and the cylclic pressure inside the cell culture membrane is also generated, 
similar to the cyclic pressure seen in the left ventricle.   
 
4.5. OPERATION OF THE CCCM SYSTEM 
The assembly of the CCCM system was performed inside the cell culture hood.  Once the 
CCCM platform station and the fluid network were assembled as in Fig. 4.13, the whole 
set up system was moved into the cell incubator.  Then, the peristaltic pump began to run, 
followed by the connection of the air network to the pressure generator, which had been 
on.  Along with the controlling from the pressure generator, the downstream tunable 
valve was adjusted until the pressure reached the desirable values.  Variable parameters, 
such as the frequency of the membrane stretching as well as the percentage of systolic 
phase per one cycle, were determined based on the requirement of each experiment.  The 
frequency of the stretching was controlled through the systolic time and the frequency 
control on the pressure generator source.  The pressure inside the cell chamber was varied 
depending on the pressure applied on the post membrane and the adjustment of the 
tunable valve.  At the end of the experiment, peristaltic pump was turned off first 




Recognizing the limitations of the 1st generation µCCCM model, the second generation 
CCCM system was created to more accurately reproduce the mechanical loading and 
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unloading conditions observed in the heart.  This system is capable of accurately 
mimicking preload and afterload experienced in the healthy and failing heart.  The 
CCCM allows for dynamic studies, accomplished via direct manipulation of flow rate, 
valve operation, membrane thickness and the height of the cell culture chamber.  When 
working with different types of cardiac cells or different physiological heart conditions, it 
is important to ensure that the type of mechanical loads delivered such as the stress, 
stretching, frequency of stretching, and the shear stress can be dynamically controlled.  











CHARACTERIZATION OF THE CCCM SYSTEM 
 
5.1. YOUNG’S MODULUS OF THE THIN PDMS MEMBRANE 
5.1.1. Introduction of PDMS 
 Polydimethyl siloxane (PDMS) is a common silicon rubber used for various applications 
such as mechanical interconnective layers between 2 wafers, mechanical-chemical 
sensors, microvalves in fluid applications, and biomedical applications.123-125  PDMS 
Sylgard 184 from Dow Corning Corporation (Midland, MI) is one of the two most 
common silicone products.  It contains a base polymer and curing agent.  Cross-linking 
reaction is the main reaction for the curing of PDMS; and this curing process is enhanced 
via heating process.126  Therefore, the PDMS rigidity can be controlled by the ratio 
between its base and cross-linking agent, the heating temperature and the time of baking.   
 
PDMS is a substrate widely used for cell behavior studies due to several advantages. 
PDMS is biocompatible, transparent, gas permeable, autoclavable, and elastic. This 
silicone is also physically and chemically stable.127 It has a high flexibility and 
compressibility, suitable to use for making a thin stretchable membrane in the CCCM 
system.  The fabrication of PDMS membrane is straight forward, less time consumed, 
and cost effective, making it suitable for replication.125  PDMS is also hydrophobic; and 
yet, via oxygen plasma treatment, it becomes hydrophilic for a few minutes before going 
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back to its original hydrophobic state.126 This special chemical characteristic of PDMS 
helps different PDMS layers bond to themselves and therefore creating a watertight seal 
between layers of the CCCM culture chamber when the PDMS becomes hydrophobic.   
 
In this project, Young’s modulus and strain value of the thin PDMS sheet used in the 
CCCM system were determined.   Due to the fact that this thin PDMS membrane is an 
elastomer and has the ability to hold a large amount of strain, true stress σ* and true strain 
ε* were determined from the engineering stress σ and strain ε of the PDMS membrane. 
Young’s modulus E of the thin PDMS membrane under the tensile force was obtained by 
the following equations: 127, 128  
                                                      
0A
F
    and   
0L
L
                  (1) 






E                     (3) 
where F is the tensile force applied onto the membrane, A0 is the original cross-sectional 
area, ∆L is the elongation of the membrane after stretched, and L0 is the original length of 
the membrane.                                                      
 
5.1.2. Tensile test 
The RSA III Rheumatics System Analyzer was used for the PDMS tensile tests.  First, 
the fabricating method for the thin PDMS sheet was described from section 4.2.  The 
ratio of mixing between the base and curing agent was 10:1.  The curing temperature was 
set at 90oC and the baking time was from 12 h or overnight.  After cured, this thin PDMS 
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sheet was cut into strips (0.5 inch x 4.0 inches) and vertically mounted in the way that 
one end of the strip was attached to a fixed fixture while the other end was clamped to a 
movable fixture of the RSA Analyzer (Fig. 5.1).  Zero force was initialized and the 
tension force was applied.  The membrane was pulled slowly with the rate of 0.5 mm/s 
until it reached a 50% displacement (2 inches).  Three different thicknesses of PDMS 
membranes (250 µm, 400 µm, and 500 µm) were used.  At least five different PDMS 
pieces molded on different days with the same thickness were made for this tensile test. 
The excel program was used to determine the stress, strain, and Young’s modulus of the 
PDMS.   
 
 
           
                      
Figure 5.1:  Experimental setup image for the strain and Young’s Modulus measurement 
of PDMS membranes.  Left: The PDMS strip (arrow) was installed between 2 fixtures of 
the RSA Analyzer.  Right: Sketch of the displacement of a thin PDMS strip.  
 











5.1.3. Results and Discussion 
The mechanical properties and Young’s modulus of different PDMS thicknesses were 
determined.  Young’s modulus of the PDMS depends greatly on the stress-strain curve, 
mixing ratio and strain rate.127  For consistency, the mixing ratio of 10:1 (base: curing 
agent) was carried throughout this project.   Tensile tests on the PDMS membrane were 
conducted.  During the testing process, the elongation of the strips and the tensile forces 
were recorded automatically by the system.  By loading the dimensions of the PDMS 
strip to the system, the engineering stress and the engineering strain were obtained.  Since 
the PDMS is an elastomer and has a capacity to hold a large amount of strain, the true 
stress and true strain derived from engineering strain were used to calculate the elastic 
modulus of the PDMS (Fig. 5.2.)  The results shows that with the PDMS thickness from 
250 µm to 500 µm, Young’s modulus and stress-strain relationship were not significantly 
different among each membrane thickness.  The Young’s modulus of the thin PDMS 
membrane was calculated using the equation (3) in the section 5.1.1, which was around 
1.0 ± 0.17 MPa.  The graph of stress vs strain and Young’s modulus value agree with the 
results obtained from other research groups.126-128  These results were helpful to assist the 
fabrication of various membranes with different thicknesses for cardiac culture.  Amongst 
these three membrane thicknesses, membrane with the thickness of 500 µm was used for 




Figure 5.2:  Graphs of stress versus strain of thin PDMS sheets   
 
5.2. PRESSURE GENERATED INSIDE THE CCCM CELL CHAMBER 
A synergistic relationship exists between the pump flow rate, membrane thickness, down-
stream resistances and the magnitude of pressure pulses within the CCCM.  All these 
parameters need to be set precisely to ensure proper filling and ejection of fluid from the 
cell culture chamber and mechanical stresses. The pressure waveform generated from the 
CCCM cell culture chamber was determined by the pressure input from the pulsatile 
pneumatic pump, frequency, flow, percentage between the stretching and contracting 
phases of each cycle as well as the downstream resistance. These variable parameters 
were determined and adjusted based on the requirement of each experiment.  The 
frequency of the stretching was controlled by the frequency set up on the pressure 
generator.  The pressure inside the cell chamber was mainly varied by the cyclic pressure 
applied on the post membrane and the adjustment of the tunable valve.  For the proof of 









































hypertension, hypotension, heart failure, bradycardia, and tachycardia)111 seen in the left 
ventricle of human heart were generated inside the cell culture chamber of the CCCM 
system. (Table 5.1 and Fig.5.3.)  This accomplishment indicates that this CCCM system 
can be a benefit for in-vitro cardiomyocyte studies under the effect of physiological 
mechanical relevance of different heart conditions.  
 
Table 5.1: Hemodynamic parameters corresponding to the left ventricular mechanical 
loading during various clinical conditions were replicated using the CCCM system.  
These parameters include heart rate, systole as percent of the cardiac cycle, end systolic 
pressure, and end diastolic pressure of the left ventricle were applied to the CCCM 
system to obtain the pressure waveforms in the following figure 5.3 below.  LV (left 
ventricle).  
 














75 40 125 9 
Hypertension 
 
75 40 183 6 
Hypotension 
 
75 40 95 6 
Heart Failure 
 
75 40 100 27 
Tachycardia 
 
200 50 120 4 
Bradycardia 
 









Figure 5.3:  Pressure vs time plots representing the changes in pressure within the 
CCCM cell culture chamber for different human heart conditions.  The parameter of the 
pressure and frequency were determined based on different conditions seen in the left 
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5.3. STRAIN OF THE PDMS CELL CULTURE MEMBRANE 
As the cell type changed from H9C2 cells to embryonic chick ventricular cardiomyocytes 
as the primary cell line for characterization of the CCCM chamber, we set the CCCM 
strain to replicate the strain of the in-vivo chick embryonic left ventricle cardiomyocytes 
at stage of 36; which is reported to range from 0.10 to 0.20. 129, 130 For in-vitro CCCM 
culturing, strains of 8-15% were applied.  
 
When fluid was induced to the cell culture chamber, PDMS experienced both radial and 
circumferential stretches (Fig. 5.4).  These stretches of the PDMS membrane were also 
conveyed to the cells seeded on that membrane.  Both strains were determined via the 
simulation from the ANSYS software program as well as via experimental membrane 
deflecting movies obtain from a Ultra Sound system.  
 
Figure 5.4:  Scheme for the stretches of the circular membrane 
 
5.3.1. Membrane Deflection Strain measurement via ANSYS program 
The following formulas were used for calculation: 
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 Mooney- Rivlin strain energy (5 parameters) for hyper-elastic material (PDMS) 
  Ψ= C10(T1-3)+C01(T2-3)+C11(T1-3)(T2-3)+C20(T1-3)2+C02(T2-3)2+(1/d)(J-1)2          (4) 
C10,C01,C20,C11,C02 = material constants 
d = material incompressibility parameter 
T1 ,T2, T3 = invariants of the right Cauchy-Green deformation tensor 
 Volume: 
                                               
 
                                       (5) 
V: volume; R: radius; and  h: height 
 
 Radial strain    : 
                                              
      
  
                                   (6) 
             Rf and Ri: final and initial radius of the membrane (Fig. 5.5) 
 Circumferential strain      (Green strain equation):  
                                                  = 0.5(λc
2-1)                             (7a) 
                                                λc=(2πrf )/(2πri )                          (7b) 
λc:  circumferential stretching ratio;  rf and ri: final and initial radius at horizontal 
position 
 
Instead of using fluid flow model to create the membrane deformed, different pressure 
scales were applied. In this perspective, it was assumed that for a small amount of fluid 
loaded to the cell chamber, the shape of the extending PDMS was similar to the semi-
sphere.   In this case, 44µl fluid was applied for 1.3cm diameter membrane. This value 
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was selected based on the condition of the experiment for the embryonic chick ventricle 
cell culture that was performed later in chapter 6.  From equation 5, the maximum 
deflection (or height) was estimated. This maximum deflection value (h = 0.33mm) was 
used as a reference for the deflection profile of the cell membrane generated by the finite 
element analysis (FEA).   
 
Finite element software ANSYS 14.5 (Southpointe, PA) was utilized to generate the 
membrane deflecting profile as a function of applied pressures.  The PDMS membrane 
was modeled using SHELL 281 with 2D, axi-symmetric boundary condition.  For this 
simulation, it was assumed that PDMS membrane was hyper-elastic material; therefore, 
Mooney-Rivlin strain energy was used to declare the physical properties of PDMS 
membrane,122 and large deflection mode was turned on. The thickness of the membrane 
was 500 µm and a Poisson’s ratio was 0.49. The membrane was assigned with fixed 
boundary conditions at the edges, and the pressure was applied evenly on the top of the 
membrane.  For each run, a certain pressure value was applied to the membrane until the 
maximum deflection of the membrane (h ~ 0.33mm) was obtained. Once the 
displacement profile (Fig. 5.6) was obtained, the radial and circumferential strains of the 
membrane were determined (Fig. 5.7).  The radial strain from the center to the edge was 





        
                      
                  
Figure 5.5: Schematic demonstration for radial strain (left) and circumferential strain 






                                                        Displacement (mm) 
 
Figure 5.6:  The sketch of PDMS membrane deflection (d = 13.0 mm, t = 0.5 mm) using 




                      
                                                                       
          
Figure 5.7:  Plots of displacement and strain of the circular PDMS membrane. [A] Plot 
of the PDMS membrane displacement from ANSYS and [B] Estimation of radial strain 
(▲) and circumferential strain (■) on the thin polymeric membrane at the bottom of the 
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5.3.2. Strain measurement via real set-up experiment 
Besides using Finite Element Analysis (FEA) to estimate the membrane deflection and 
strain 122, we used high resolution ultrasound Imaging (Vevo-2100, Visual Sonics Inc, 
Toronto, Canada) to examine the membrane displacement of the real set-up system. A 
MS-400 probe (30 MHz) was used for recording the cyclic movement of the membrane 
(Fig.5.8.).   
 
                  
  
                                         
Figure 5.8: Images of experimental set up for taking real-time video of the PDMS 
membrane deflections using the Ultra Sound system.  [A] Image of the Vevo2100 high 
frequency ultrasound system used for the PDMS strain measurement.  [B] Experimental 
set-up for the strain measurement with [1] probe and [2] CCCM platform where the 
CCCM culture chamber was installed. 
 
 
Three different experiments were set up with three different 500 µm thick PDMS 






the base to its peak of 10mmHg, and the frequency was set at 2.0 Hz with 40% diastolic 
phase. To ensure that CCCM system worked correctly and the membrane deflection was 
in the right range for each membrane, manual ejections of different fluid volumes (25 µl 
and 50 µl) were performed besides the real set-up experiment (Fig. 5.9.).  
                             
Figure 5.9:  Ultrasound images of PDMS membrane deflection at 0, 25, and 50 µl fluid 
loading along with the real set-up experiement.  From these images, the level of 
membrane stretch from the experiment is located between 25µl and 50µl injections.  
 
For each ultrasound movie, the deflecting movement of the PDMS membrane was 
converted to single moving slides (30 slides /sec). The base slide and the maximum 
deflecting slides were selected for each measurement (Fig.5.10.).  Using an ad hoc 
program developed in MATLAB (Mathworks, Natick, MA), reference points and 
displacement points along the membranes from the base line and the maximum deflecting 
slides were created evenly along the membrane to determine the Ri and Rf.  The 
deflection profile was then created to calculate the strains, and the radial, as well as the 
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circumferential strain of these membranes, were therefore calculated using the equations 
(6) and (7a-b).  
 
5.3.3. Conclusion  
In addition to the pressure stimulation, stretch levels in cardiac cells play a critical role 
ensuring cell phenotype and function.  In the CCCM system, cardiac cells were attached 
and grown on a soft matrix which is laid on the thin PDMS membrane.  Therefore, the % 
strain of the PDMS membrane represents the stretch level of the cells growing on it.  
With two different methods for strain measurement, the strain profile for the PDMS 
membranes was found to match the strain experienced by cardiomyocytes within the 
native ventricle.  These results confirm that the PDMS membrane could replicate in-vivo 













                    
                    
                     
                       
  
Figure 5.10:  Results of the PDMS membrane deflection. [A] Slide of base line where no 
fluid was loaded to the system.   [B] Slide of the maximum PDMS membrane deflection. 
The vertical lines were created to divide the membrane in even distances between 2 
edges.  [C] Image of reference points on the base line (green color) and displacement 
points along with the deflecting curve (blue color). [D] Graphs of circumferential strain 
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5.4. SHEAR STRESS MODELING 
The dimension of the cell culture well is similar to the dimension of the previous 
µCCCM model.  The height of the later model is 0.5cm higher than the height of the well 
in the µCCCM model. Therefore, a design guideline published in the prior work (for the 
µCCCM system111)  was applied to ensure that the depth of the cell culture wells was 
>0.5 cm, resulting in low shear recirculation at the bottom of the wells.   This work was 
performed by Vahidreza Parichehreh, the co-author of the previously published 
manuscript.111  Below is the detail copy of method and results from the previous work for 
shear stress modeling in the µCCCM system. 
 
5.4.1. Method 
Finite element software ANSYS Academic Teaching Advanced 12.0, FLOTRON 
module, was used to determine the wall shears stress as a function of channel height and 
flow rate.  A 2D simulation was applied and environment was verified for steady 
incompressible flows. For the simulation, it was assumed that no-slip boundary 
conditions for the channel and groove walls, and that the participating fluid has the same 
physical properties of water with the density of 1000 kg.m-3 and the dynamic viscosity of 
10 Pa.s.  The inlet fluid flow rate was set at 8.6 mL/min and zero pressure was applied to 
the outlet.  The fluid domain was meshed using 2D quadrilateral element, FLUID141, to 
model steady state fluid.  A segregated sequential solver algorithm was used; that is, the 
matrix system derived from the finite element discretization of the governing equation for 
each degree of freedom was solved separately.  The mesh was refined through mesh 
sensitivity analyses: at each simulation, the elements showing high velocity gradients 
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were refined, until reaching convergence of sensitive measures of the predicted 
quantities. 
 
5.4.2. Results  
Four wells with different depth (0.25, 2.00, 4.00, and 8.00 mm) were used; and a velocity 
of ~ 0.024 m/s (corresponding to 8.6 mL/min) at the inlet of the wells was applied in all 
the experiments.  The shear stress (τ) was determined using the equation 131                                                                       
                                                          
dy
du
     
 where τ is the shear stress(dynes/cm2), µ is viscosity coefficient (kg/(m.s)), u is the fluid 
velocity (m/s). The viscosity (µ) of water at 1atm and 20o C is 1.0 x 10-3 kg /(m.s).131 
 
5.4.3.   Discussion 
 
The flow velocity simulation (Fig.5.11.) showed that for the wells with depth of 2.00, 
4.00, and 8.00 mm, with the flow rate of 8.6 mL/min, the flow velocity was nearly 0.00 
m/s at the bottom of the well whose height is higher than 0.25mm.  Indeed, the result 
from ANSYS shows that the shear stress was 0.00 dynes/cm2 to approximately 200 µm 
above the bottom of the wells with the height higher than 8.0 mm. The second generation 
CCCM system has the same diameter of cell chamber and same dimensions of fluid inlet 
and outlet; but the height of the chamber is about 10.00 mm.  With this height, definitely, 
fluid flow will not create a significant shear stress, affirming that cell cultured in the 
second generation CCCM won’t expose to the shear stress.  In addition, this 
characterization confirmed that this system can be able to manipulate the shear stress 




                          
Figure 5.11:  Flow velocity simulation for the cell culture chamber of the µCCCM.  Note 
that the flow velocity are almost 0.00 m/s at the bottom of the wells except the 0.25mm 
deep well, meaning fluid movement does not touch the bottom of these wells; therefore, 




Overall, the characterization of mechanical properties of thin PDMS membrane and 
pressure, strain, and shear stress affirmed strongly that the CCCM can be used to 
replicate the in vivo heart function.  This replication can be accomplished through a 
combination of different variables such as membrane thickness, the height of the cell 
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chamber and adjustment of tunable components, including the tunable valve, the 




USING THE CCCM SYSTEM FOR CARDIOMYOCYTES STUDIES  
 
6.1. BUILDING THE EXTRACELLULAR MATRIX FOR CARDIAC CELL 
CULTURE  
6.1.1 Introduction  
The development of scaffolds that mimic the in-vivo extra cellular matrix (ECM) is 
crucial for the engineering tissue remodeling/regeneration. The ECM provides a 
microenvironment for cells to grow, proliferate, and migrate.  The biochemical, 
structural, and mechanical properties of scaffolds play a significant role in regulating cell 
adhesion to ECM and to neighboring cells, which in turn affect cell morphogenesis and 
differentiation.132-137  It is true especially in the case of in-vitro cardiomyocyte studies, 
the beating rate, force of contraction, and cytoskeleton structure of cardiac myocytes 
which depend greatly on the ECM.132, 133, 138, 139  Therefore, cardiac cells need to be 
seeded and grow on a soft cell culture matrix, similar to the in-vivo heart tissue.  In this 
study, collagen matrix was used.  Based on the paper published,16, 140 the cell culture 
matrix used for cardiac tissue was determined via the morphology and spreading of cells 
similar to the in-vivo physiology.  Therefore, the concentration of the collagen used for 




In addition, to ensure that the collagen ECM was not rapidly digested by the 
cardiomyocytes during the experiment, crosslinking with glutaraldehyde was applied to 
the matrix.  Glutaraldehyde is a cross-linking agent that is commonly used for collagen-
based biomaterial.141, 142  Finally, for the cell to attach and grow on the cross-linked 
collagen ECM, a gelatin solution containing fibronectin was also added to the matrix 
prior to the cells seeded.   
 
6.1.2. Fabrication of the ECM 
First, the sterilized PDMS cell culture chamber was treated with oxygen plasma to create 
a hydrophilic surface (March RIE, 200 mmTorr, 200 mmHg, 10% oxygen, 30 seconds). 
Then, a 300 μL of the collagen type I solution (0.67 mg/mL) was promptly added to the 
cell culture chamber and allowed to be cured at 37°C for 3-4 h.  Second, a 400 μL of 
0.5% (w/v) glutaraldehyde solution was gently added on the surface of the cured collagen 
matrix and maintained for 1 h at room temperature (RT).  After 1 h, the matrix was 
washed with deionized (DI) water three times, followed by a 4N sodium hydroxide 
solution twice (30 min/each).  Finally, DI water was used again for the final wash (three 
times).   The cell chamber was filled with DI water and stored at 4 °C for later use.  48 h 
before cells were seeded, a 400 μL solution composed of  10% gelatin attachment factor 
(1X, Gibco, S- 006-100)  and 50 μg/mL of fibronectin (BD Biosciences, 356008) was 
added to the chamber. A one-time washing with 1X PBS or fresh culture medium was 
performed before the cells were seeded. 





                                      
Figure 6.1:  Image of the collagen matrix with cardiac cells after 4 day cultured in the 
CCCM system.   
 
6.2. CULTURING CARDIOMYOCYTES IN THE CCCM SYSTEM 
6.2.1. Primary embryonic chick ventricular cardiomyocytes 
Embryonic chick cardiac cells are commonly used to study the complex processes 
leading to normal or abnormal heart development.   Chick embryonic heart development 
is quite similar to that of the human heart.  Fertile chick eggs are relatively easy to obtain 
and less expensive than rodent models.  Finally, it is possible to observe the embryonic 
heart at the earliest stage of its embryogenesis and to isolate embryonic cardiomyocytes 
for in-vitro culture.15, 79, 143  
 
 During the embryonic period, cardiomyocytes have a high proliferation rate and 
differentiation.16  The synthesis of DNA from the embryonic cardiomyocytes reaches its 
peak during the cardiac morphogenesis.   During this developmental window, mechanical 
hemodynamic loading and unloading play a crucial role in regulating the cardiomyocyte 
92 
 
morphogenesis, architecture, and contractile functions and stimulating different 
molecular signal pathways.  On the other hand, in response to these mechanical 
stimulations, embryonic cardiomyocytes themselves regulate their proliferation and 
differentiation rate. Therefore, any changes in mechanical hemodynamic loading and 
unloading system affect the development of cardiomyocyte tissues and their contractive 
functions greatly. 
  
Chick embryonic heart development can be divided into 46 stages, called Hamburger 
Hamilton (HH) stages.79, 144  These stages are used rather than only using days of 
incubation due to variations in maturational rate that occur in response to changes in 
ambient environmental factors.  The first myocardial differentiations are detected on 
stage HH7 when the formation of the endocardial heart tube begins. On HH 8, the 
process of heart tube fusion starts, and is completed on HH 11.  Heart beat begins on this 
11th HH stage.  During stages between the 13 to the 18, the heart tube transforms to the C 
shape loop then to the S-shape loop to form atria and ventricles. HH 18-22, the primary 
ventricular channels can be observed.  HH 21-34, valve development, vasculature, atrial 
and ventricular septations are gradually formed, along with other cardiac components, 
such as the cardiac conduction system, atrial-ventricular (AV) nodes or cardiac neural 
crest.  Ventricular septation is completed around HH 34.  HH 36 (or day 10 gestation), 
the Purkinje fiber network begins to form and the atrial-ventricle valve is completely 
formed to separate the atria from the ventricle.  HH 40-41 is the hatching stage.  Besides 
the HH stage, the stages of embryonic heart development can also be named based the 
incubation day.  The chick hatches on approximately the 21st day of incubation.  Primary 
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cardiac morphogenesis occurs between day 2 to day 10 of a 21-day gestation.  Day 10 is 
corresponding with HH36, where the ventricles are completely separated.  Therefore, we 
selected 10th day embryonic chick ventricles for cell isolation in our CCCM experiments.  
 
Embryonic cardiac development depends on the integration of the environmental 
conditions, biomechanical forces, molecular programming, and adaptive remodeling. 
Cyclic mechanical stimulation inside the heart induces myocardial hyperplasia.  In 
addition, in the early period of cardiac morphology, the function of chick embryonic 
cells, including the adaption of the contractile function, is greatly affected by mechanical 
loading conditions.  Mechanical stimulation thus affects the formation of the shape, as 
well as the growth of heart chambers.  Indeed, applying mechanical stimulation during 
different stages of the embryonic period will greatly affect the function of the heart 
tissue, which includes cell proliferation, contraction, frequency, and the duration of 
contraction.  Heart cells start beating synchronically and strongly, similar to the in-vivo 
nature, reached the peak in-vitro on culture day 12.16 Therefore, the heart embryonic 
tissue increased active contractile force from culture day 7 to day 12.  Also, culture day 
12 has the highest proliferation.  However, the contractile response to the β-adrenergic 
stimulation was less than culture day 9.  Under these studies, 3 different developing 
stages were standardized for mechanical stimulation: from culture day 4 to 6 (before the 
cells increase the contraction force), from culture day 9-11 (before the proliferation goes 





6.2.2. Embryonic chick cardiomyocyte isolation and culturing   
6.2.2.1. Embryonic Chick Cardiomyocyte Isolation and seeding  
Fertile White Leghorn chicken eggs (Utah) were incubated in a forced-draft, constant-
humidity incubator until day 10 of the gestation (HH: stage 36).  Ventricles were 
collected and enzymatically digested using 2 mg/mL of collagenase type II, followed by 
0.05% trypsin-EDTA solution (Invitrogen, Carlsbad, CA). The cell solution was then 
filtered and isolated cells were collected.  An 1 h pre-plate for  the isolated cells at 37oC 
was performed in 10 mL of cell culture medium (DMEM high glucose, 10% Fetal Bovine 
Serum, 1% embryonic chick extract, and 1% antibiotic), followed by a 5 min centrifuge 
at 1000rpm.  Cell pellet was then re-suspended in a new 10 mL of cell culture medium 
and were cultured on a gyratory shaker (60−70 rotations/min) for 18 h to re-aggregate 
viable cardiomyocyte clusters.  The following day, the whole cells, clusters, and medium 
were collected and spun at 1000rpm for 5 min.  Old medium was discarded and 1ml of 
warmed fresh medium was added.  Cell clusters were counted and cell viability was 
checked with Trypan blue staining. For each cell culture chamber prepared from the 
session 6.1.2, approximate 500µl of 3.0−3.5 × 104 cell clusters were seeded and cultured 
in a static condition at 37 °C, 5% CO2 for 3 h before filling the reservoir with warmed 
fresh culture medium.  A static culture condition at 37oC and 5% CO2 was maintained for 
24 h to obtain 100% confluence.  On the following day, the sample was subject to 





6.2.2.2. Culturing cardiac cells under the influence of mechanical stimulation within 
the CCCM 
Day 10 embryonic chick cardiomyocytes experience in-vivo peak pressures of ∼10−15 
mmHg and radial and circumferential strains of ∼10−20%.130  Since the cardiac cell 
tissue is thinner and weaker than the in-vivo cardiac tissue, a peak systolic pressure of 10 
-12 mmHg and a strain of 8-15% were chosen for the whole experiment.  To culture 
cardiomyocytes under these conditions, a 500 μm thick membrane was selected and a 
flow rate of ∼2.6 ml/min was used to attain a filling volume of 44 μl per cycle. 
  
Following 24 h of culturing under static conditions to achieve 100% confluence, the cell 
culture chamber with cells was transferred to the CCCM system and the system was 
assembled as described in the section 4.3.  The whole set-up CCCM system was then 
moved into the cell culture incubator and was ready for mechanical stimulation for 4 days 
at 37 °C and 5% CO2.  The static pressure inside the cell culture chamber was reported 
before the peristaltic pump was turned on.  The flow rate was set at ~2.6 ml/min (~ 44 
µl/cycle).  The downstream one-way valve and the pressure from the generator were 
adjusted to obtain cyclic pressures of 0-10 mmHg at a frequency of 2.0 Hz. Pressure 
waveforms were checked in a period during 4 day stimulation. For comparison, the 
control samples were cultured under a static condition in the same culture incubator with 
the same amount of fresh culture medium.   After 4 days, the cell culture chamber was 
removed from the CCCM platform and then maintained under a static condition for ∼3 h 





During the CCCM stimulation, the instantaneous pressure generated inside the cell 
chamber was obtained using a high fidelity pressure transducer and LabView software. 
Based on the percentage of systolic versus diastolic timing set on the pressure generator, 
along with the pressure waveform and fluid volume loaded to the chamber, the pressure-
volume loop for a single working cycle of the CCCM was obtained (Fig. 6.2.).  
      
 
Figure 6.2:  Plot of pressure vs time and pressure-volume loop obtained within the 
CCCM system. The changes in pressure within the CCCM cell culture chamber and 
pressure−volume loop correlating changes in pressure with changes in volume within the 
CCCM chamber was determined. The parameters of the pressure and fluid volume were 
set up based on the parameters from the left ventricle of the embryonic chick heart. 
Similar to the pressure-volume loop seen in the left ventricle of the heart, this pressure-
volume loop represents the (a) filling phase, where the pressure was low but the volume 
increased,  (b) the isovolumic contracting phase, where the pressure increases 








ejection phase, where the fluid was ejected out of the chamber, and (d) the isovolumic 
relaxing phase where the pressure drop significantly with no change in the fluid volume.   
 
After 4 days in the mechanical stimulations, the tissues were removed from the system, 
followed by tissue analysis. Observed under the microscope, the stimulated construct has 
more cardiac islands on the surface and looked more crowded and rougher, while the 
control has a flatter surface with larger sized cells (Fig.6.3.).  
 
  
Figure 6.3:  Phase contrast images of in-vitro embryonic chick cardiac cells cultured 
under the static and CCCM stimulated conditions.  Left: embryonic chick cardiac cells 
cultured under the static condition as a control.  Right: embryonic chick cardiac cells 
cultured under mechanical stimulations generated within the CCCM system.  Compared 








The CCCM system is able to mimic the mechanical conditions which occur in the left 
ventricle.  Primary chick embryonic left ventricle cardiomyocytes are able to grow well 
under the influence of cyclic mechanical stimulation generated within the CCCM system.   
Further analysis between the stimulated and the static cultured groups will be described 
below, included tissue alignment, beating rate, maturation, proliferation, and gene 
expression.    
 
6.3. CARDIAC TISSUE ALIGNMENT AND PROLIFERATION  
6.3.1. Introduction 
Cardiomyocytes continuously experience the stress and the change in length during the 
heart cycle, due to the blood loading and unloading.  Cardiac tissues are elongated during 
diastolic phase and shortened during the systolic phase of a heart.  These hemodynamic 
stress and tissue strain affects cell proliferation and cytoskeletal remodeling.84  Indeed, in 
response to the strain and stress, cardiomyocytes have the ability to remodel cell shape by 
adding the sarcomere in series or filaments in parallel respectively to maintain cardiac 
function.145 In addition, cardiomyocytes during embryogenesis have a high proliferation.  
Staining nucleus with Bromodeoxyuridine (BrdU) along with DAPPI is a common 
method to check the cell proliferation.  
Proliferation =                   







6.3.2. Methods and materials 
Immunofluorescence staining was used to evaluate the cell alignment and proliferation. 
To examine the cell alignment, the constructs were stained with F-actin and α-actinin.  
Before staining, the samples were fixed with 4% paraformaldehyde (PFA) at room 
temperature (RT) for 20 min, followed by a washing with 1X phosphate buffered saline 
(PBS) solution.  A 0.1% Triton solution was then added to the constructs for 30 min, RT.  
A solution of 0.5% BSA in 1X PBS was used as a blocking solution.  For F-actin 
staining, the samples were incubated with TRITC-conjugated Phaloidin (1:100; 
Millipore, Billerica, MA) in the blocking solution for 1 h at RT.  For α-actinin, primary 
antibody cardiac α-actinin EA53 IgG1(1:400, Abcam, Ab7817) and second antibody anti-
mouse (1:600, 488 green, Invitrogen, A21121) in 1% BSA/1X PBS  solution were 
applied individually to the tissue  for 1 h, RT, alternated with a washing buffer (0.05% 
Tween-20/1X PBS) 1 h in between.  DAPPI (1:100, Millipore, 90229) was also applied 
to stain the nucleus at the end.  Finally, the tissue constructs were mounted with anti-fade 
solution (Invitrogen, San Jose, CA), and imaged using a Nikon A1 confocal microscopy 
system (Nikon Instruments, 284 Melville, NY).    
 
To examine cell proliferation, Bromodeoxyuridine (BrdU) incorporation during DNA 
synthesis was utilized.  Basically, 48 h prior to the tissues being fixed with PFA, 20 μM 
of BrdU (Sigma) was added to the cell culture medium both for the control and the 
stimulated tissues. After being removed from the present culture environment, the tissues 
were fixed with 4% PFA solution for 20 min at RT and permeablized with 0.1% Triton 
solution for 30 min at RT.  A one hour washing with 1X PBS solution was performed 
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before the HCl solution (1N) was added directly to the tissue on ice for 10 min. A 1N 
HCl solution was then replaced by 2N HCl solution.  After sitting at RT for 10 min, the 
tissues in the 2N HCl solution were incubated at 37oC for an additional 20 min.  A one 
hour washing with 1X TBE buffer (10X TBE, Mediatech Inc., Manassas, VA, 46-011-
CM) at RT was performed before the tissues were blocked with a blocking solution (1% 
BSA + 0.1% glycine in 1X PBS) for 1 h at RT.  The tissues were then incubated with the 
primary antibody Anti-BrdU (1:100, Abcam, ab1893) in the blocking solution for 24 h at 
RT.  After 1 h washing with the washing buffer, the tissue was incubated with secondary 
antibodies, anti-sheep (1:400, red, Abcam, Ab6743) in the blocking buffer for 1 h at RT, 
followed by another 1 h washing.  DAPI (1:100, Millipore, 90229) was then added to 
stain the nucleus at the end.  Finally, the tissue constructs were mounted with anti-fade 
solution (Invitrogen, San Jose, CA) and imaged using a Nikon A1 confocal microscopy 
system (Nikon Instruments, 284 Melville, NY).    
 
6.3.3. Results 
Specimens were stained with F-actin and cardiac alpha-actinin antibodies, and then 
examined under the confocal microscopy with 60X magnification. Compared to the 
control group, embryonic chick heart cells in the CCCM tissue samples were more 
aligned and oriented (Fig.6.4.).  The parallel orientation showed up obviously in the 
CCCM construct stained with F-actin.  The cell arrangement of the control sample 






                               
 Figure.6.4: Immunofluorescence images of cardiomyocyte tissue cultured in the CCCM 
system and in the static condition.  (A) Images of the cell skeleton structure with f-actin 
(green).  The stimulated tissue cultured in the CCCM system gave more parallel 
arrangement compared to the random arrangement of the control tissues cultured under 
the static condition   (B) Images of cell alignment with α-sarcomeric actinin (red).  The 
picture of the CCCM construct shows in-vivo like matured tissues with stripped and 
closer connection between cell-to-cell connections.  The blue color is the nucleus stained 
with DAPPI.  
 
To determine the cell proliferation, BrdU, the marker stained for nuclei that have 
synthesized new DNA during the BrdU treatment period, was used.  Different locations 
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of the constructs were observed under 60X magnification of the confocal microscope 
(Fig.6.5.).  The dividing cells had nuclei that showed both blue and red colors 
overlapping each other, while the undivided cells showed only blue nuclei.  Red nuclei 
without blue were the dead cells.  The cell proliferation rate was determined by the ratio 
between the dividing cells to the total of living cells.  Six different experimental sets were 
done for data statistical analysis.  
       
          
Figure 6.5:  Results from immunofluorescence BrdU staining for cell proliferation.  [A] 
Immunofluorescence images of BrdU staining. Red: the nucleus stained with the BrdU 
antibody; blue: nucleus stained with DAPPI. The dividing cells had both blue and red 
nuclei; the undivided cells showed only blue nuclei; dead cells showed only red nuclei 



















The sample size was N = 6 with two tailed significance was set at ** p  0.05, meaning a 
strong chance of having statistical significance between these 2 groups. 
  
6.3.4. Discussions and conclusions 
The alignment of cardiomyocytes and the cell proliferation were evaluated via immune-
fluorescence microscopy.  Cardiomyocytes were subjected to mechanical stimulation.  
Cell alignment expresses more in mature cells.  Therefore, cardiomyocyte maturation was 
observed under the immunofluorescence images via Phaloidin and sarcomeric α-actinin.  
The result shows that the contraction-stretching of the cells promotes the increasing of F-
actin and helps to align the cells.  Cell alignments demonstrated that mechanical loading 
spontaneously rearranged the cytoskeletal orientation of the cells.  In addition, from BrdU 
staining, a higher proliferation rate was observed on the CCCM tissues rather than on the 
control ones. This result suggests that applying mechanical stimulations on the embryonic 
cardiac tissue is necessary to promote the cell alignment and proliferation rate of the 
cardiomyocytes. 
 
6.4. CARDIAC TISSUE MATURATION 
6.4.1 Beat rate 
Beat rates (BR) of the conditioned and control constructs were obtained after being 
removed from the CCCM for 3 hours.  Two different time frames of the CCCM 
stimulations (4 and 7 days in the CCCM system) were performed.  At least 10 different 
experiments on different dates were performed. The BR of the stimulated samples was 
almost 1.5 times higher than the BR of control samples (Fig.6.6).  In addition, the BR of 
104 
 
the stimulated samples cultured in the CCCM system for 7 days yielded a little higher 
than the BR of samples with 4 days stimulation, whereas the controls of both groups are 
the same.  This indicates that mechanical stimulations are important to maintain and 
enhance the BR of the cardiac tissue.  
                       
Figure 6.6:  Graph of the beat rate (beats per min) between the control and the stimulated 
groups. 2 different periods of mechanical stimulations (4 days and 7 days) were 
performed along with their controls cultured under a static condition. Number of samples 
was N=10. Two tailed significance was statically set at **p  0.005. 
 
6.4.2. Electrical Pacing  
Electrical pacing of stimulated constructs and unstimulated controls was accomplished to 
identify changes in electrical properties in response to mechanical conditioning in the 
CCCM.  Platinum wire electrodes (d=0.5mm, Alfa Aesar, Ward Hill, MA, 43288) were 
embedded vertically into the tissue-collagen gel matrix and connected to an electrical 























         
 
Figure 6.7:  Electrical Pacing Setup System.  [A] The image of the real pacing 
experiment, which was set on the stage of the microscope before pacing the tissue.  [B] 
Diagram of the electrical stimulating, which was programed on the electrical pacing 
system.  
 
The maximum pacing tissue beat rate was recorded while varying the threshold voltage. 
To find the maximum pacing rate, the voltage was increased from the lower to the higher 
voltage until the BR reached to 2:1 phase (BR was half of the maximum BR).  The 
threshold voltage was also determined.  This voltage was the voltage at which the tissue 
started beating with the frequency of 2.0 Hz.  The results show that the CCCM tissues 
reached their maximum BR of 245bpm, which is close to the BR of the in-vivo mature 
chick cardiac tissue (Fig. 6.8).  In addition, the threshold voltage needed for the CCC 
tissues to reach the frequency of 2.0 Hz was lower than the threshold voltage inserted on 
the control samples.  This result affirms that mechanical conditioning within the CCCM 
resulted in tissue maturation represented by more efficient cell-cell connections and 





Figure 6.8:  Pacing Electrical Stimulation Results.  [A] The Maximum Pacing Beat Rate 
(bpm) between the non-stimulated (light blue) and the stimulated cardiac tissue group 
(red).  [B] The Threshold Voltage (V) in corresponding to the maximum pacing beat rate 
for the non-stimulated and stimulated cardiac tissue groups.  N= 6 with two-tailed 
significance set at ***P<0.05 
 
6.4.3. Cell contractility 
Movies of beating cardiomyocyte were recorded and analyzed to determine regional 
tissue strain during contraction.  For an individual sample, 5 different locations on the 
movie were selected randomly for strain measurement.  Lagrangian strain calculation for 
finitely small displacement was used as previously described by Bonet et al.146  Briefly, if 
p1 and p2 are two nearby points defined on the first frame, and d1 denotes the Euclidian 
distance between p1 and p2 at the first frame (i.e., reference frame), then dj denotes the 
Euclidian distance between these two points at time frame j, then, the engineering strain 
S, at frame j, is defined as: 































A custom algorithm was written to estimate the Lagrangian strain. First, the peak 
displacement was determined by tracking two points based on their appearance features 
through the image frames and calculating the displacement between the two points over 
the image frames. The maximum displacement was then selected as the reference frame. 
Then, five pairs of points on the first (reference) frame were determined and their tracked 
pairs on the selected frame with maximum displacement.  The Lagrangian strain for each 
pair of points was estimated using equation (8). Finally, the mean Lagrangian strain was 
calculated as expressed a % shortening. 
 
The results show that without the electrical pacing, the percentage shortening of the 
CCCM stimulated tissues was about 4.49 ± 0.88%, whereas controls were only at 2.73 ± 
1.8% (Fig. 6.9). The unpaired t-test shows no statistical significance between the 
shortening length of the control and the CCCM samples. However, when electrical 
pacing was applied, the shortening of the CCCM stimulated tissues increased to 5.52 ± 
0.88%, whereas the shortening of the un-stimulated tissue only went up to 2.96 ± 1.79%.  
The statistical results showed significant difference with *p<0.05.  These results suggest 
that, the mechanical stimulation enhances the shortening of the cardiac tissue, and this 





Figure 6.9:  Graph of cardiomyocyte shortening with and without electrical stimulation: 
control (black) and the CCCM stimulated (clear) samples evaluated with and without 
electrical pacing.  N=6 with two-tailed significance set at *P<0.05 
 
6.5. CARDIAC TISSUE RESPONSE TO β-ADRENERGIC STIMULATION 
6.5.1. Introduction 
Isoproterenol (ISO) is a β-Adrenergic Agonist which binds to G-protein coupled β-
Adrenergic receptors (β-AR).  The coupling of ISO/β-AR activates adenylyl cyclase 
(AC).  These activated AC catalyze the conversion of Adenosine triphosphate (ATP) into 
cyclic adenosine monophosphate (cAMP), followed by the activation of protein kinase A 
(PKA). After activated, PKA is able to phosphorylate L-type Ca2+ channel and 
phospholamban (PLB); as a result, increase the Ca2+ influx into the cytosol and enhance 
the activity of sarcoplasmic reticulum Ca2+ pump SERCA2a to transport Ca2+ from the 
cytosol into the sarcoplasmic reticulum (SR).  Un-phosphorylated PLB inhibits the 
activity of the SERCA2a pump.  Phosphorylating of β-AR via PKA prevents the coupling 





















summary, ISO and β-AR play a significant role in the intracellular mediate signal 
transduction pathway by enhancing the Ca2+ influx into SR and the transportation of Ca2+ 
from the cytosol into the SR, therefore, contributes to regulate the heart function via 
contractility and frequency.   
 
ISO affects the chick embryonic ventricle development as early as day 4th (out of a total 
of 21 days of gestation before hatching) via the increase of contracting force of cardiac 
tissue.  In contrast to the mature heart, ISO does not affect the early embryonic heart until 
the expression and coupling of functional β-AR.  In addition to the positive chronotropic 
and inotropic effects of ISO stimulation, ISO treatment also has a toxic effect on 
developing and mature cardiomyocytes and can trigger cell death in cardiomyocytes from 
a wide range of species.147-149  In adult hearts, ISO continues to enhance the rate of 
tension development and beat rate (BR) of the tissues.150  Our hypothesis that, if 
mechanical stimulation enhances the maturation of the cardiac tissue, in comparison to 
the control tissue group, the contractility and the BR of the stimulated tissue group must 
be increased in response to the ISO administration.   
 
6.5.2. Material and Methods 
Embryonic chick cardiac left ventricle cells at day 10 were isolated, seeded, and 
experimented as mentioned in the previous sections.  After being cultured for 4 days with 
mechanical stimulation within the CCCM system, cardiac tissues were removed from the 
system and incubated in a static condition at 37oC for another 3 hours before applying 
ISO to the tissue.  After 3 h, samples were brought to a microscope for analysis. Different 
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concentrations of ISO (0.5µM, 1µM, 5µM, 10µM, and 50µM) (Sigma Aldrich, I6504) in 
warmed fresh medium were applied respectively to the tissues.  An electrical hot plate 
was used to keep the temperature of the tissues and medium at 37oC.  BR before and after 
administrations were reported; and contractile movies were made within 5 minutes of 
each ISO administration.  Then, a brief washing with warmed fresh culture medium was 
performed before adding a new higher dose of ISO to the tissue. Contractile movies were 
analyzed using MATLAB software (MathWorks, Naticks, MA) to determine the 
percentage shortening for tissue contractility.  
 
6.5.3. Results 
The effect of ISO on the BR and contraction of the constructs cultured in the 
mechanically active CCCM system and in static conditions were observed.  The BRs 
before and after each ISO application were recorded.  The BR of the tissue before the 
0.5µM ISO solution added to the tissue was used as the referent BR to determine the 
percentage change in BR under the effect of ISO administrations (Fig.6.10).  The results 
show that the BR of the CCCM group increased in response to increasing doses of ISO to 
a maximal response at 10µM ISO, then declined.  In contrast, the BR of the control group 
decreased in response to increasing doses of ISO above 0.5µM.  This result indicated that 
the ISO produced a toxic response in static (unconditioned) chick cardiomyocytes. 
However the CCCM stimulated group had positive chronotropic responses to ISO, 




                               
Figure 6.10: Plot represents the percentage change in beat rate of the cardiac tissue under 
the effects of Isoproterenol.  While the control group showed cellular toxicity with 
increasing ISO concentration, the beat rate of the stimulated group increased and reached 
its peak at 10µM ISO.  The horizontal line is the base line corresponding to the referent 
beat rate recorded before the ISO applications.  Five experiments were performed. 
 
Cardiac contractility with and without ISO was also examined.  Movies of each ISO 
application were made and maximum contraction was chosen to determine tissue 
shortening.  Shortening was calculated as described in the section 6.4.3.  With ISO 
applications contractility of the stimulated tissues significantly increased versus the 
unstimulated group, to 7.55 ± 0.78% versus 4.52 ± 0.43%, respectively (Fig. 6.11). In 






















Isoproterenol concentration (µM) 
Stimulated Control
N = 5 
P ≤ 0.01 
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unconditioned group.  These results suggest that mechanical stimulation may have 
accelerated CM maturation as measured by reduced toxicity and increased BR and 
shortening in response to ISO stimulation.  
Figure 6.11:  Changes in the cardiomyocyte contraction with and without the influence 
of ISO: controls (black) and CCCM stimulated (clear) constructs.  Measurements were 
made at 3 different locations on each sample. N= 6 different paired experimental sets. 
Two tailed significance was set at ***p ≤ 0.001. 
 
6.5.4. Discussion 
Catecholamine affects mechanical performance of the heart tissues through the activation 
of β-AR; and the cardiovascular function is controlled primarily on this adrenergic 
signaling pathway.52-54  Under normal physiological conditions, catecholamine induces 
positive inotropic and lusitropic responses in the heart tissue through β1-AR-activated 
pathway.  Once stimulation of β1-ARs via ISO binding occurs, cAMP accumulation 
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rapidly increases which indirectly promotes the phosphorylation of PLB, and enhances 
the cardiac contractility.  Out of their subtypes, subtype β1-ARs exhibits dominantly 
when cardiomyocytes become more mature under normal physiological condition.53, 56 
This dominant β1-ARs, therefore, induces positive inotropy and lusitropy via heart rate 
and contractility.  Under the abnormal physiological condition of the heart, or failing 
heart, β1-ARs decreases, but β2-ARs increases, causing cardiomyocyte death.56   
 
After adding the ISO to the tissue, the CCCM conditioned constructs yielded a higher 
percentage of contraction compared to the control ones; and the BR of the conditioned 
tissue kept increasing until a 10 µM ISO solution (2.5mg/ml) was added.  However, for 
the controls, the concentration of ISO higher than 10µM created negative inotrope and 
reduced BR on the cardiac tissue, and finally the cardiac tissue stopped beating  This 
result is similar to the result found in the early studies from Serverin,151 indicating that 
these CM undergo cell damage and death if a higher concentration of ISO is applied.  
These results state that, compared to the static cultured control group, the CCCM 
stimulated construct has a higher response to the β-AR, and at the same time, has a higher 
resistance against the cellular toxic effect of ISO, hence, is less likely to undergo cell 
damage and death.   Higher response and higher resistance may be the result of higher 
cell-cell connection, more maturity, or more population.  In conclusion, mechanical 
stimulations of embryonic CM in the CCCM resulted in a more mature ISO response, 





6.6.   SELECTED CARDIOMYOCYTE GENE AND PROTEIN EXPRESSIONS IN 
RESPONSE TO MECHANICAL CONDITIONING 
6.6.1. Introduction 
From previous results, embryonic chick cardiac tissues cultured in this CCCM system 
showed a higher proliferation rate, better alignment, and more maturation via BR and 
contractility.  This section focusses on the effect of mechanical stimulation on proteins 
that play a critical role in the beating rate and contractility of the heart tissue. Along with 
the 2D constructs (CCCM stimulated and the control ones), ventricle tissues at day 16, 
cell suspension from day 16th (same day harvesting the 2D constructs), and 3D 
engineered cardiac tissues (ECT) harvested at culture day 5 (equivalent to day 16 chick 
ventricular cells) were also collected for selected gene expression and protein synthesis 
analysis.  
 
As markers of CM maturation and function, sarcoplasmic reticulum calcium ATPase2a 
(SERCA2a), phospholamban (PLN), Troponin T (TnT), and Alpha and Beta-Myosin 
Heavy Chain (α-, β-MHC), and total protein were analyzed in control and conditions 
tissues.   
 
SERCA2a and PLB are essential proteins that regulate calcium cycling inside the 
cardiomyocytes.  These genes are involved in regulating the contraction-relaxation of the 
heart muscle. Un-phosphorylated PLB binds to SERCA2a, prevents Ca2+ binding to 
SERCA2a, and acts as an endogenous inhibitor of SERCA2a.  Phosphorylated PLB 
(pPLB) releases this inhibitory effect, making the affinity site to Ca2+ on SERCA2a more 
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apparent.  This activated SERCA2a then transports calcium against the gradient from 
cytoplasm back to sarcoplasmic reticulum (SR).58  As the result, the rate of calcium ions 
influx back to the SR increases, promoting the muscle relaxation prior to the next cycle of 
calcium release and myofiber contraction.   Therefore, SERCA2a has a central role in 
regulating Ca2+ cycling between the SR and myofibers and a direct impact on CM 
contractility.  The regulation of SERCA2a activities plays a critical factor in the 
contractile function and heart disease.152 32   
 
TnT is the protein binding with tropomyosin and involved in the regulation of thin 
filament function and the interaction between the thin and thick filament during myofiber 
shortening.50  Abnormalities of this TnT gene are associated with sudden death in cardiac 
patients.  Myosin heavy chain (MHC) is the major sarcomeric protein expressed in heart 
tissue during development and adulthood and regulates mechanical performance of the 
heart, especially muscle contractility.64-66  Alpha and Beta MHC are the two important 
isoforms of the MHC found in the heart tissue.  β-MHC isoform is expressed mainly 
during embryogenesis or heart diseases.  α-MHC isoform exists dominantly in the adult 
heart tissue and inhibits the expression of β-MHC. The ratio of  α-MHC to β-MHC 
expression is also seen in species with rapid or slow beating rates67  
 
6.6.2. Methods 
6.6.2.1. Cell suspensions and 3D ECT constructs 
Cell suspension from ventricular cardiomyocyte tissues from day 16 were also isolated 
using GentleMACS™ Dissociator (MACS Miltenyi Biotec, Auburn, CA), pre-plated, and 
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rotated before being collected for cDNA and proteins.  At the same time, ventricular 
tissues from day 16 were also collected for cDNA and proteins. 
 
To create 3D ECT constructs for PCR, the isolated embryonic cardiomyocyte clusters (~ 
3.0 x 104 clusters) were also mixed with collagen solution (0.667mg/ml) and seeded in 
the TT-4001C Tissue Train™ plates (Flexcell® International Corporation, HillSborough, 
NC) using Flexcell FX5X Tension system until the collagen solution was cured (about 
1.5 h vacuumed, 37oC, 5% CO2) .  Then the constructs were cultured under the static 
condition for 5 days prior to analysis for PCR.  
 
6.6.2.2. Real time PCR (qPCR) for gene expression 
Total RNA was extracted from the cardiac constructs, cell suspensions, or ventricles, 
using the Trizol isolation method.  Briefly, the sample was homogenized in 1ml Trizol 
three times (7 sec/each) in ice.  After RNA isolation, cDNA was then transcribed via the 
RNeasy mini kit (QIAGEN).  The concentration of cDNA was measured using the 
NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA).  The real time 
PCR for each target gene was then performed in triplicate. The GAPDH primer was 
included as the housekeeping gene. SERCA2a, α and β MHC, TnT, and PLB were the 
interested genes chosen for these PCRs.  For data analysis, the relative quantification of 
each target gene in each group was normalized to GAPDH.  The fold change of each 





6.6.2.3. Western blotting for protein synthesis 
The end of the experiment, total protein of each sample was collected using the 
Complete-Lysis M solution (Roche Diagnostics, Indianapolis, IN). The protein 
concentration was then determined, using the NanoDrop 2000 Spectrophotometer. The 
target proteins were separated using 10% SDS-PAGE and transferred to Immobilon™-FL 
membranes (Millipore Corporation, Bedford, MA).  After being blocked with 5% non-fat 
milk, the membrane was probed with different primary antibodies including anti-
SERCA2a (1:500) (LSBio, Seattle, WA), anti α-MHC (1:150) (Santa Cruz, Dallas, TX) 
and β-MHC (1:500) (Bioss, Woburn, MA), anti-Actinin (1:500) (Abcam, Cambridge, 
MA), anti TnT (1:1000) (Sigma, St. Louis, MS) and anti β-actin (1:3000) (Cell Signaling, 
Beverly, MA).  The secondary antibody was Cy3®goat anti-Rabbit IgG (1:500) (Life 
Technologies™, Grand Island, NY) and Cy5® goat anti-mouse IgG1 (1:500) (Abcam, 
Cambridge, MA). The labeled bands representing the target proteins were visualized via 
the Typhon 9400 system.  NIH Image J software program was used for densitometry.   
 
6.6.3. Results and discussions 
6.6.3.1. Gene expression 
Figure 6.12 and figure 6.13 show that compared to the level of gene expression in the 
embryonic chick ventricle, gene expression decreased progressively from cells 
suspension to 2D CCCM culture for all three genes: SERCA2a, α-MHC, and β-MHC.  
The gene expression on 2D constructs, both the controls and the CCCM stimulated 
samples, was much lower compared to the heart ventricles and cell suspension on day 
16th, as was shown in a previous study.93 When compared, the 2D constructs together, 
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gene expressions between the control and the CCCM group showed no significantly 
statistic increase or decrease.  The p values were greater than 0.05.  However, gene 
expressions of these genes were partially restored with the 3D ECT constructs especially 
with PLN, α-MHC, and β-MHC genes .    
  
 
Figure 6.12:  Plots of fold changes in gene expression with ventricular gene expression 
set as the control state. [A] SERCA 2a gene expressions, [B] PLN gene expression. All 










































    
Figure 6.13: Plots of fold changes in gene expression with ventricular gene expression 
set as the control state. [A] α-MHC gene expressions and [B] β-MHC gene expressions. 
All samples were collected on day 16th (out of 21 days of gestation).  N ≥ 3 and p > 0.05. 
 
Figure 6.14 shows the total RNA synthesis obtained from 2D cardiac construct groups: 
the control and the stimulated ones.  From the plot, the embryonic chick cardiac tissues 
stimulated yielded more RNA (1803 ± 218 ng/µl) than the tissues cultured under the 

















































Figure 6.14: Total RNA obtained from 2D embryonic chick cardiac tissues.  Total 
samples N = 3, **p < 0.05 
 
6.6.3.2.  Protein Synthesis 
More than 10 samples in pair (controls vs the CCCM stimulated groups) were used to 
determine the total protein in each group.  The total protein in the CCCD stimulated 
constructs significantly increased (97.15 ± 4.97 mg) versus total protein in the 2D 
controls (71.52 ± 4.14 mg) (Fig. 6.14)  
                    
Figure 6.15: Total proteins of the 2D cardiac tissue constructs.  N ≥ 12 two tailed 





































Five different CM proteins (SERCA2a, α- and β-MHC, α-Actinin, and TnT) were 
selected for the Western Blot (Fig. 6.16).  Figure 6.17 and figure 6.18 show the target 
proteins collected from different conditions.  Proteins SERCA2a, TnT, and β-MHC from 
the cell suspension were much lower than those in the ventricular tissues. Interestingly, 
the amount of α-Actinin protein almost doubled after cell isolation from ventricular 
tissue. As noted in the previous study, protein levels decreased in response to 2D culture. 
However, when mechanically conditioned in the CCCM system, protein levels were 
modestly increased, except for myosin heavy chain proteins.   
  
Figure 6.16: Images of Western Blot bands of the interested proteins in the 2D control 








Figure 6.17: Graphs of SERCA2a, α- and β-MHC proteins normalized by β-Actin.  [A] 
SERCA2a protein, [B] α-MHC protein, and [C] β-MHC protein.  N ≥ 3 and two tailed 




















































Figure 6.18: Graphs of TnT and α-Actinin proteins normalized by β-Actin.  [A] TnT 
protein and [B] α-Actinin protein.  N ≥ 3. SEM was used for error bars; and two tailed 
significance was set at * p < 0.05 and **p<0.005. 
 
6.6.4. Discussion 
During cell isolation, cell-cell contacts are disrupted and extracellular matrix is 
destroyed, causing cells to lose the extra cellular network connections that influence 





































negative impact of cell isolation is the disruption of gene expression and protein synthesis 
of contractile relating proteins.93  As a result, gene expression and protein synthesis of the 
Ca2+ regulating protein (SERCA2a) and contractile proteins (β-MHC) were lower in the 
cell suspension group than in the ventricle group.  However, these results also 
demonstrate that transcriptional and translational processes still occur and that viable  
cardiomyocytes recover and mature in the CCCM. The protein α-MHC obtained from the 
cell suspension was higher than those in the ventricular tissues, but was not statistically 
significant.  However, when these embryonic cardiac cells were cultured under 3D, gene 
expressions of α-MHC, β-MHC, and PLN were augmented, demonstrating that 3D 
culture is necessary for the cardiac tissue to fully regulate the transcriptional processes. 
These results are similar to the results done by L.Khait and R.K.Birla group with neonatal 
rat tissues.93   2D constructs are compacted, cells are laid on top of each other; therefore, 
limiting their ability to arrange their orientation and their potentials to create their own 
cellular matrix as well as to access their nutrients. 3D constructs allow cells more space 
to rearrange their orientation, create their own cellular matrix, and build up their 
connection among cells.  Nutrients are easy to access.  Therefore, when cells were 
cultured under 3D condition, their gene expressions are nearly restored to levels found in 
the 3D native ventricular tissues even though all these 3D ECT constructs in this 
experiment were cultured under the static condition.  
 
In contrast to other CM associated proteins, the protein synthesis of α-Actinin protein 
doubled in the short time from ventricle tissue to cell suspension.  The amount of Alpha-
actinin was also higher than those in the ventricular tissues. In cardiac cells, α-actinin 
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protein is the cytoskeletal actin-binding protein to stabilize the contractile apparatus.42, 153, 
154 Once the extra-cellular network was disrupted during the isolation, this protein 
synthesis may be augmented due to the greater need in order to maintain the integrity of 
cardiac function and stabilize the shape of the cells.  
 
For 2D constructs, compared to the control unstimulated group, SERCA2a protein 
synthesis in the stimulated tissue increased.   However, the result from gene expression 
showed no statistically significant change in the SERCA2a gene expression including the 
3D ECT constructs. In the cardiac cells, the sarcoplasmic reticulum where Ca2+ is stored 
during the relaxing phase becomes functional only around birth and embryonic chick CM 
are known to have immature SR;155 hence, it is understandable to show no significant 
difference in SERCA gene expression.  Further, the level of PLN in the CCCM tissues 
was not significantly increased, compared to the static culture tissue, indicating that cells 
did not undergo negative regulation in response to mechanical stimulation within the 
CCCM system.  In addition, the amount of total protein obtained from the conditioned 
group was higher than the control one.  All these results affirm that mechanical 
stimulation during embryogenesis mainly enhanced proliferation rate rather than increase 
gene expression for SERCA.  Understanding these biomechanical responses of the 
cardiac embryonic cells will be important for engineering myocardial tissue studies.  
 
The two cardiac MHC isoforms reciprocally shift their expression depending on the 
developmental stage and physiological condition of the heart.  Before birth, β-MHC is the 
main MHC isoform in the ventricle.  After birth, β-MHC reduces dramatically but α-
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MHC increases significantly and becomes the main MHC isoform.  The reversal of these 
2 MHC isoforms is seen under heart failure diseases or in an aging heart in which β-
MHC is dominant.  Our results showed no significant change of the α- and β-MHC gene 
expression and the protein synthesis within 2D construct groups. First, no increase in the 
β-MHC gene expression indicates that tissues undergoing mechanical treatment in the 
CCCM system may become more mature and are not overstressed, which was supported 
by the PLB gene expression level above.  Second, this study was performed during the 
embryonic and fetal stage, five days before hatching, indicating that the α-MHC 
expression will not be dominant yet. Third, the expression of these isoforms is controlled 
by thyroid hormone T3.64  Applying mechanical stimulation at an early stage of cardiac 
tissue development may not be enough to promote α- and β-MHC gene expression, as 
well as protein synthesis. In fact, the gene expressions and the reciprocity of these MHC 
isoforms are controlled by developmental stages and thyroid hormone T3. 64, 156  
Therefore, for further maturation of the tissue, besides mechanical conditions, the thyroid 
hormone needs to be included to generate more MHC, especially when dealing with 
embryonic cardiac tissue engineering for tissue transplant.  
 
6.7. CONCLUSION 
We have demonstrated that early mechanical stimulation during embryogenesis is needed 
for tissue proliferation, maturation, responses to the β-adrenergic agonist, and protein 
synthesis. Mechanical stimulations also help to maintain the calcium regulation inside the 
cells. These results prove that CCCM system is a novel system to insert the in-vitro 
mechanical stimulation on cardiac tissue; therefore, holds significant promise for 
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generation of functional cardiac patches for replacement of injured cardiac tissue.  3-D 
cell culture in CCCM with incorporation of thyroid hormone and mechanical stimulation 












CVD continues to be a major global healthcare dilemma. Current treatment options, 
though beneficial, have significant limitations.  In order to address these issues and 
provide new treatment options, a better understanding of the molecular pathophysiology 
of CVDs is necessary.  Cellular level models provide the best platform for discovery 
based studies.  However, current approaches for cardiac cell culture fail to accurately 
replicate the mechanical loading conditions seen in-vivo as a consequence of normal 
hemodynamic loading and unloading.  Available techniques address mechanical loading 
on an individual basis, but to date, no system that accurately replicates the in-vivo 
mechanical loading environment exists.  This has resulted in cell-level studies being 
conducted in environments with little or no physiological relevance. 
 
The CCCM system was designed and developed to culture various cardiac cells in a 
physiologically relevant environment by replicating the mechanical loading conditions 
generated as a consequence of normal hemodynamic loading and unloading.  Various 
variables like cyclic pressure, strain and shear can accurately be replicated in a pulsatile 
fashion similar to conditions experienced in the left ventricle of a heart.  Characterization 
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studies show that mechanical loading profiles associated with normal and various disease 
conditions of the human heart, including heart failure, hypertension, hypotension, 
bradycardia and tachycardia can be accurately replicated over extended periods of time.  
Finally, proof-of-concept studies using primary chick embryonic ventricle 
cardiomyocytes confirms the ability of this system to generate in-vivo like mature cardiac 
tissue cultured within this platform in phenotype, function and gene expression.   
 
Thus far, characterization and proof-of-concept demonstrations were accomplished using 
this CCCM system.  Confirmation of the ability of the CCCM system to accurately 
mimic the in-vivo cardiac environment allows for the design and study of various 
conditions associated with CVD.  These future studies are likely to include 
cardiomyocyte regeneration such as stem cells or adult cardiomyocyte regeneration using 
a mechanical loading environment, study of cardiac and aortic endothelial cells under 
conditions of continuous and pulsatile flow,114, 115 and finally evaluation of drugs and 
other treatment options using cardiac cells maintained under various disease conditions.  
 
7.2. LIMITATIONS 
The CCCM system, however, has some limitations, including its complexity, the absence 
of an authentic 3D cell culture, and lack of electrical and hormonal factors.  First of all, 
due to the complication of the system (tubes, valves, and multiple layers), it is time 
consuming to set up one experiment which includes the cleaning, setting, and operating 
processes.  These can easily create a high risk of cross-contaminations.  Second, ECM 
was constructed before seeding the cells; once seeded, the cells attach well on the surface 
of the ECM.  Generated tissues hence cannot be easily detached from the crosslinking 
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collagen matrix, which can create a serious issue for tissue transplant or tissue 
regeneration.  Thirdly, cardiomyocytes cultured in this system are in 2 dimensions on the 
top of the gel matrix, not inside the matrix, therefore lack of a 3D ECM model, which 
affects the development of the cardiac tissue including gene expression. Finally, beside 
physiological and mechanical aspects, in-vivo cardiomyocytes are influenced by electrical 
and hormonal stimulation. Mechanical, hormonal, and electrical aspects need to be 
incorporated simultaneously for cardiomyocyte culturing.  
 
7.3. FUTURE WORK 
The CCCM system opens a wide opportunity to understanding the behavior of cardiac 
cells on molecular and cellular levels.  It also provides an excellent tool to regenerate 
mature cardiac tissue for tissue transplant, which is our ultimate goal.  From the previous 
chapters, cardiac tissues cultured in the CCCM system become more mature via higher 
beat rate, more alignment, and stronger contraction,.  However, in this study, cardiac cells 
were cultured on the surface of a soft collagen matrix and under mechanical stimulations 
of a normal heart condition.  For tissue regeneration or tissue transplant, it is necessary to 
generate the 3D tissue without collagen matrix attached.   For molecular and cellular 
studies, understanding the impact of mechanical stimulation for different cardiovascular 
conditions on a heart tissue is crucial to provide a better treatment options for CVD.  In 
addition, with electrical pacing, the beating rate and the contraction increase significantly. 
This electrical pacing for the in-vitro cardiac tissue can be considered as the sinoatrial 
node in the heart, which generates impulses to the cardiac tissue at the greatest 
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frequency.110  With these perspectives, the future works for this CCCM project might 
include: 
1. Using higher vertebrate (mammalian) tissues with 3D cell culture 
Embryonic chick cardiac cells have been commonly used in studies.  However, tissues 
from higher mammal levels are more relevant to the human tissues.  Also, cardiac tissue 
is more physiologically relevant to the in-vivo cardiac tissue if it is cultured within a 3D 
matrix.  In addition, it is much better to use human iPS cell lines to study cardiac tissue 
behavior and regenerate tissues.  Similar to the Flexcell system, 3D cell culture can be 
done in the cell culture chamber.  In this case, the crosslinking matrix ring serves as an 
anchor for the cell to attach and keep the tissue from forming a ball.  Primary testing 
results (not shown) proves that this technique can be used for cardiac culture under the 
mechanical stimulation in the CCCM system and warrants further investigation.   
2. Studies the effects of mechanical stimulations from various heart conditions  
Chapter 5 shows that this CCCM system is capable of replicating different pathological 
conditions.   Molecular and cellular studies of cardiac tissue under pathological 
conditions can be specifically investigated.   
3. Create a co-existing electrical and mechanical stimulation within the system.  
Pilot studies with the CCCM system were conducted with simultaneous electrical and 
mechanical stimulation.  The next step is to build a network for field electrical 
stimulation inside the cell chamber.  When mechanical stimulations causing the tissue to 
go up and down, stretched and contracted, the electrical network must ensure that it won’t 
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